

## Anti-obesity interventions in Mexican Population

1 Looking for crumbs in the obesity forest: anti-obesity interventions in the Mexican population. History,  
2 and systematic review with Meta-Analysis

3

4 Running title: Anti-obesity interventions in Mexican Population

5 Key words: Anti-obesity agents, abdominal obesity metabolic syndrome, systematic review, Meta-  
6 analysis, randomized clinical trials, type 2 diabetes (T2D).

7 The Síntevi Group

8

9 Esperanza M. Garcia-Oropesa<sup>1†</sup>, Yoscelina E. Martinez-Lopez<sup>2†</sup>, Sonia María Ruiz-Cejudo<sup>3, 4</sup>, José  
10 Darío Martínez-Ezquerro<sup>3, 5</sup>, Alvaro Diaz-Badillo<sup>6,7</sup>, Carlos Ramirez-Pfeiffer<sup>7</sup>, Alejandra Bustamante-  
11 Fuentes<sup>8</sup>, Elena B. Lopez-Sosa<sup>9</sup>, Oscar O. Moctezuma-Chavez<sup>10</sup>, Edna J. Nava-Gonzalez<sup>11</sup>, Adriana L.  
12 Perales-Torres<sup>12</sup>, Lucia M. Perez-Navarro<sup>13</sup>, Marisol Rosas-Diaz<sup>1</sup>, Kathleen Carter<sup>14</sup>, Beatriz Tapia<sup>15</sup>,  
13 Juan C. Lopez-Alvarenga<sup>6,7\*</sup>

14

15 1 Laboratorio de Biología Molecular, Unidad Académica Multidisciplinaria Reynosa Aztlán (UAMRA),  
16 Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.

17 2 Programa de Doctorado en Ciencias de la Salud. Universidad Nacional Autónoma de México (UNAM).  
18 Mexico City, Mexico.

19 3 Unidad de Investigación Epidemiológica y en Servicios de Salud, Área Envejecimiento (UIESSAE),  
20 Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS). Mexico City, Mexico.

21 4 Programa de Maestría y Doctorado en Música, Cognición Musical, UNAM, Mexico City, Mexico.

22 5 Centro de Ciencias de la Complejidad (C3), Universidad Nacional Autónoma de México (UNAM),  
23 Mexico City, Mexico.

24 6 Department of Human Genetics. University of Texas Rio Grande Valley. Edinburg, Texas.

25 7 Posgrado Universidad Mexico-Americana del Norte. Reynosa, Tamaulipas, Mexico.

26 8 Escuela de Medicina, Universidad Panamericana. Mexico City, Mexico.

27 9 Cirugía General. Hospital Español. Mexico City.

28 10 Asociación Odontológica Mexicana para la Enseñanza y la Investigación. Mexico City.

## Anti-obesity interventions in Mexican Population

29 11 Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey, Nuevo  
30 León, Mexico.

31 12 Laboratorio de Bromatología. Unidad Académica Multidisciplinaria Reynosa Aztlán (UAMRA),  
32 Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.

33 13 Servicio de Nefrología, Dirección de Investigación, Hospital General de México Dr. Eduardo Liceaga,  
34 Mexico City.

35 14 Research and Education Library of the School of Medicine. Education & Academic Affairs. University  
36 of Texas Rio Grande Valley. Edinburg, Texas. United States of America.

37 15 Faculty Development, Associate Professor, Department of Pediatrics. University of Texas Rio Grande  
38 Valley. Harlingen. Texas.

39

40 † These authors have contributed equally to this work.

41 \*Correspondence:

42 Juan C. Lopez-Alvarenga

43 [juan.lopezalvarenga@utrgv.edu](mailto:juan.lopezalvarenga@utrgv.edu)

44

45

46 Tables in the manuscript: 5

47 Figures in the manuscript: 10

48 Supplemental tables: 2

49 Supplemental figures: 3

50

## Anti-obesity interventions in Mexican Population

51

### 52 Abstract

53 Mexicans and Mexican Americans share culture, genetic background, and predisposition for chronic  
54 complications associated with obesity and diabetes making imperative efficacious treatments and  
55 prevention. Obesity has been treated for centuries focused-on weight loss while other treatments on  
56 associated conditions like gout, diabetes (T2D), and hypertriglyceridemia. To date, there is no systematic  
57 review that synthesize the origin of obesity clinics in Mexico and the efforts to investigate treatments for  
58 obesity tested by randomized clinical trials (RCT).

59 We conducted systematic searches in Pubmed, Scopus, and Web of Science to retrieve anti-obesity RCT  
60 through 2019 and without inferior temporal limit. The systematic review included RCT of anti-obesity  
61 treatments in the Mexican adult population, including alternative medicine, pharmacological, nutritional,  
62 behavioral, and surgical interventions reporting biometric outcomes such as BMI, weight, waist  
63 circumference, triglycerides, glucose, among others. Studies with at least three months of treatment were  
64 included in the meta-analysis.

65 We found 634 entries, after removal of duplicates and screening the studies based on eligibility criteria,  
66 we analyzed 43, and 2 multinational-collaborative studies. Most of the national studies have small sample  
67 sizes, and the studied strategies do not have replications in the population. The nutrition/behavioral  
68 interventions were difficult to blind, and most studies have medium to high risk of bias.  
69 Nutritional/behavioral interventions and medications showed effects on BMI, waist circumference, and  
70 blood pressure. Simple measures like plain water instead of sweet beverages decrease triglycerides and  
71 systolic blood pressure. Participants with obesity and hypertension can have benefic effects with  
72 antioxidants, and treatment with insulin increase weight in those with T2D.

73 The study of obesity in Mexico has been on-going for more than four decades, but the interest on RCT  
74 just increased until this millennium, but with small sample sizes and lack of replication. The interventions  
75 affect different metabolic syndrome components, which should be analyzed in detail with the population  
76 living on the U.S.-Mexico border; therefore, bi-national collaboration is desirable to disentangle the  
77 cultural effects on this population's treatment response.

## Anti-obesity interventions in Mexican Population

78

### 79 Introduction

80 Obesity phenotypes have been reproduced in arts and culture since the dawn of humanity. The Venus of  
81 Willendorf, made 25 to 30,000 years BCE during the upper Paleolithic and currently exhibited in the  
82 Natural History Museum in Vienna, is a figure depicting a woman with abdominal obesity symbolizing  
83 femininity, beauty, and fertility. In Mexico the artistic expression in the well-preserved Bonampak, which  
84 literally means painted wall, shows the Mayan ruling family of Bonampak, led by King Chaan Muwan  
85 and his wife Lady Rabbit (1). The scenes painted between 790 and 792 AD show human figures with  
86 signs of overweight or obesity. Other figurines from western Mexico show male abdominal distension,  
87 some of them may represent fat, ascites, cancer, or other underlying conditions with controversial  
88 significance (2).

89 For centuries, treatments for obesity have been described, mainly focused on weight loss and as a  
90 treatment for other secondary conditions such as gout and diabetes. In Greek and Roman art, obesity  
91 generated displeasure and sarcasm, being caricatured as an excess of alimentary and sexual stereotypes.  
92 This deviation from the norm was unacceptable in ancient Greek art, and they called by the term  
93 “Hippocratic Corpus” what we now call *morbid obesity*. The cause of obesity was considered the excess  
94 of fluids circulating in the body, therefore, the treatment consisted of restricting the fluid balance through  
95 diet, exercise, and medications. Since then, side effects of treatments have been described, like any  
96 leanness of the body causes corrugation of the skin, or if a woman is pregnant there would be risk of  
97 miscarriage.(3) The literature brought contrasting characters like Sancho Panza and Don Quixote, or  
98 Falstaff and Hamlet, stereotypes from Cervantes and Shakespeare, respectively. This jolly fat figure  
99 remains in traditional celebrations like the image of Santa Claus contrasting with slim Scrooge (4).

100 In the eighteenth-century, the medical literature documented the association of obesity with fatigue, gout,  
101 and breathing difficulties. Fat was considered reprehensible and medically undesirable. The progression  
102 of nutrition as science with direct calorimetry measurement experiments from Atwater and Benedict (5)  
103 between 1898 and 1900 analyzed the law of the conservation of energy applied to living organisms'  
104 metabolism. They made a detailed description of demographic characteristics in men, diet, physical  
105 activity recorded in their “Metabolism experiments”. During the last century Vague (6) described the  
106 well-known android and gynecoid morphologies. He measured the perimeter and thickness of adipose  
107 tissue with calipers. Obesity has become a recognized clinical entity, subject of research and treatment  
108 with medication and behavioral techniques.

109 In the United States, Mexican Americans are considered part of the Hispanic Americans or Latino group.  
110 The U.S.-Mexico border represents this minority with active immigration, and a rapid increase in  
111 population. One of the Healthy People 2020 goals was to improve the health of all groups, requiring an  
112 understanding of the Hispanic culture, and health care needs for health promotion (7).

113

114

## Anti-obesity interventions in Mexican Population

### 115 Obesity in Mexico, a story never told

116 The Obesity Clinic started in 1959 at the Instituto Nacional de Nutricion Salvador Zubiran, by Dr. Luis  
117 Domenge, Dr. Carmen Ramos and Dr. Jorge Gonzalez-Barranco. Obesity was considered as an aesthetic  
118 but also a medical problem. The so-called epidemiologic transition, from infectious to chronic  
119 degenerative diseases, moved slowly from the 70s and 80s. The evolution of treating obesity as a medical  
120 problem was promoted by Dr. Gonzalez-Barranco based on scientific research and clinical trials with  
121 medications in the 90s.

122 The first attempt to classify obesity was using the Metropolitan Life Insurance Company (MLIC) which  
123 developed standard tables for “ideal” (MLIC 1942) and then “desirable” weight (MLIC 1959) based on  
124 the observed association of body weight with mortality. These standard tables were the platform for  
125 developing the current definition for underweight, normal, overweight, and obese individuals based on the  
126 body mass index (BMI) cut-offs (8).

127 The use of BMI as a reliable measurement started with the NHANES from 1988 to 2016. These studies  
128 demonstrated the age-adjusted prevalence of obesity in the United States increased progressively: from  
129 22.9 to 39.6 percent. The main issue of concern in regard to BMI involves the growing obesity epidemic  
130 and the increasing population with high BMI numbers (9).

131 Since 1993 a series of population surveys were conducted systematically in Mexico using the BMI. The  
132 first National Survey on Chronic Diseases (ENEC from Spanish: Encuesta Nacional de Enfermedades  
133 Crónicas) highlighted obesity as a national public health problem. The prevalence of obesity in Mexico  
134 has increased substantially since the 1980s, and currently affects over 30% of the adult population (10).  
135 The epidemiological transition from undernourishment and infectious diseases to emergent chronic  
136 diseases were well documented in the ENEC. A sequel of undernourishment in presence of an obesogenic  
137 environment is homeorrhexis as an adaptive response to undernourishment. Homeorrexis or homeorhesis  
138 comes from the Greek homós, 'equal'; and rhéxis, 'violent rupture', and refers to regulatory mechanisms  
139 that allow the body to change from one homeostatic, stable condition to another in a programmed fashion,  
140 e.g. growth during childhood or the onset of lactation (11). A combination of genetic and socioeconomic  
141 strata were conditions affecting stature. From North to South Mexico the ENEC data show a decrease in  
142 stature by expenses of the lower body segment (Figure 1), the sitting height is almost similar across  
143 regions. The stature can modify body composition despite BMI (12) and can be an indicator of  
144 socioeconomic inequality (13).

145 The First Obesity meeting in Mexico with the NAASO and the Pan-American Endocrine Meetings were  
146 held in Cancun in 1997. These meetings were a landmark achievement for the study of obesity in Mexico  
147 with the first NOM (Mexican Official Norm) for obesity management, published in 1998 (14). Since this  
148 new millennium, there has been a spread of interest in obesity in other hospitals and Mexican states.  
149 Close collaboration with the Diabetes Division at the University of Texas San Antonio Health Science  
150 Center (UTSAHSC) and the South Texas Diabetes and Obesity Institute (STDOI) at the UTRGV has  
151 been done since then.

152

## Anti-obesity interventions in Mexican Population

### 153 Importance of gathering scientific literature in Mexico

154 Mexican Americans are spread all over the United States, the National Health and Nutrition Examination  
155 Surveys 1988-1994 showed children aged 4 to 17 years who born abroad had significantly lower  
156 prevalence of overweight / obesity compared to Mexican American children born in the U.S. (PR = 0.77,  
157 95% CI: 0.61, 0.96). In contrast, during 2005-2014, there was no evidence of a difference in overweight /  
158 obesity at birth (PR = 0.95; 95% CI: 0.84, 1.07) and no differences with newer immigrants (<5 years  
159 living in the U.S.) compared with those born in the U.S. (15).

160 Regarding the diet quality, Yoshida et al., (16) reported age differences in diet quality influenced by  
161 acculturation (customary adoption of a new culture): older Mexican Americans had higher scores in  
162 Healthy Eating Index (HEI) indicating a better diet quality. For vegetables, fruits, and proteins, middle-  
163 aged adults had higher scores compared to young adults. Concerning HEI components, a 1-unit increase  
164 of acculturation was associated with 10% to 20% lower odds of attaining better scores for vegetables,  
165 fruits, dairy, sodium, and empty calories in almost all ages.

166

### 167 Medication research and current anti-obesity guidelines

168 Some pharmacokinetics determinants of many drugs depend on the body size; for instance, obesity  
169 modifies the volume of distribution, and drug clearance, probably due to increased activity of cytochrome  
170 P450 2E1 and possible modifications on tubular reabsorption (17).

171 However, not only biology can explain the variability on losing weight, other factors are associated with  
172 the feasibility of following medical recommendations affected by cultural environment. The importance  
173 of lifestyle was defined in early times of weight loss intervention but was debated by the use of  
174 medication.

175 Numerous international published guidelines for anti-obesity treatment consider the local disparities and  
176 cultural differences of each geographic region. The management of obesity relies on diverse medical  
177 specialists, health professionals and government decisions. Primary prevention of obesity is fundamental  
178 and requires policies for favoring spaces for physical activity and a healthy environment. Harmonization  
179 on treatment cannot be global but can help to tailor weight loss treatments, and metabolic improvement  
180 for prevention of complications.

181 Since 2000 guidelines from the former North American Association for Study of Obesity (nowadays The  
182 Obesity Society -TOS) and the NIH Working Group were mainly based on dietary therapy, physical  
183 activity, and behavior therapy, and guided on the appropriate use of pharmacological and surgical  
184 interventions. The weight loss recommendation was for patients with BMI >30 and those with BMI  
185 between 25 and less than 30 with two or more complications. They suggested that pharmacotherapy  
186 should be used only in the context of a treatment program with diet, physical activity, and behavior  
187 therapy. Once the guide was published, only two drugs were approved for weight loss, sibutramine and  
188 orlistat (18).

## Anti-obesity interventions in Mexican Population

189 The European guidelines also made emphasis on lifestyle modifications including nutrition and physical  
190 activity. The goals are risk reduction (even with modest weight loss i.e. 5-10% of initial body weight),  
191 attention on waist circumference and management of complications. They increase the number of drug  
192 treatments for obesity approved by FDA (Food and Drug Administration) and EMA (European Medicines  
193 Agency): orlistat, lorcaserin (only for FDA), phentermine/topiramate (only for FDA),  
194 bupropion/naltrexone and liraglutide. They recommend drug discontinuation if the patient does not reach  
195 5% loss of initial weight after 12 weeks of treatment. This guide discusses metabolic surgery focusing on  
196 metabolic effects as primary outcomes instead being limited to weight loss (19).

197 The Endocrine Society in 2015 published the guideline for pharmacological management of obesity (20)  
198 implementing diet, exercise, and behavioral modification and suggesting drugs may amplify adherence to  
199 behavior change, especially for patients with a clinical history of failure in non-medication treatments.

200 The nutritional health status in Mexico was affected by government policies, the first supermarket chains  
201 selling American processed food in Mexico started in the 1940s. The government eliminated the subsidy  
202 of corn tortillas in 1999 with the objective to improve competitiveness in the global economy. This action  
203 loaded in closedown local tortilla factories not able to compete. The transition epidemiology from  
204 infectious to chronic diseases was rampant in this period. In 2008 the import tariffs on maize, bean, sugar,  
205 and mill were eliminated. In response to the nutritional problems and increase in obesity, in 2010 the  
206 Ministries of Public Education and of Health published the General Guidelines for Dispensing or  
207 Distribution of Foods and Beverages at School Food Establishments (SFEs). After a mass media  
208 campaign to reduce consumption of high caloric food, the Mexican congress, in 2014, excised a tax on  
209 high energy dense food (21).

210 This study aims to perform a systematic review with meta-analysis to synthesize and evaluate the  
211 evidence of anti-obesity treatments performed in Mexican adults with overweight and obesity. These  
212 treatments can include pharmaceutical, behavioral, surgical, nutritional, and alternative interventions  
213 designed as controlled clinical trials, to compare results within and between interventions, and finally, to  
214 discuss these findings with Mexican American studies.

215

## Anti-obesity interventions in Mexican Population

216

### 217 Methods

#### 218 Protocol registration and search strategy

219 The protocol was registered in PROSPERO on 11/17/2020 and assigned the registry number  
220 CRD42020221436. The search strategies included Pubmed, Scopus, and Web of Science databases to  
221 obtain published literature up to 2019 to include randomized controlled clinical trials for obesity  
222 conducted in Mexico. To identify additional studies and gray literature, we contacted Medical Societies  
223 such as the Endocrinology Society from Mexico and researchers from academic institutions such as  
224 UNAM. For inclusion in the meta-analysis, all interventions had to be conducted for at least three months  
225 and report both baseline and final BMI. The query was focused on all interventions with overweight or  
226 obese participants who underwent weight loss treatment. We included nutritional/behavioral treatments,  
227 with knowledge that many of these interventions cannot be blinded, therefore we assessed the possibility  
228 of bias using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)  
229 approach (22). Medications, alternative medicine and surgical interventions were included in the review  
230 finished in December 2020.

231 An example of a search strategy performed in Pubmed without time period limits:

232 ("obesity"[MeSH Terms] OR "obesity"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All  
233 Fields] OR "treatment"[All Fields] OR "therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]))  
234 AND ("mexico"[MeSH Terms] OR "mexico"[All Fields]) AND Clinical Trial[ptyp]

235

#### 236 Eligibility criteria

237

238 The systematic review included Mexican adult overweight or obese participants in controlled clinical  
239 trials subjected to pharmaceutical, behavioral, surgical, nutritional, or alternative interventions. Weight  
240 loss was the primary or secondary outcomes. We included studies published in English or Spanish at any  
241 time, conducted in Mexican centers and multicentric international studies with Mexican participants. For  
242 inclusion in the meta-analysis, treatments had to be conducted for at least three months and indicate  
243 baseline and final BMI. When available, we analyzed metabolic syndrome components (i.e., serum  
244 concentration of glucose, HDL-C, triglycerides, systolic and diastolic blood pressure, and waist  
245 circumference). We followed these criteria for the articles' peer-screening and conducted a third final  
246 group review to resolve disagreements. We contacted the corresponding authors to clarify doubts and  
247 obtain additional information when necessary.

248

#### 249 Studies selection

250 We recovered 634 studies from three databases: Pubmed (n=180), Scopus (n=238), and Web of Science  
251 (n=216). After eliminating duplicate studies and applying the eligibility criteria, 589 studies were  
252 eliminated. The flux of the analyzed studies is described in Figure 2. Of the 45 included studies data were



## Anti-obesity interventions in Mexican Population

253 extracted using the Cochrane tool and quality assessed with the Jadad scale. There were 45 studies  
254 included in the qualitative synthesis and 25 in the meta-analysis. Of the studies included in the qualitative  
255 synthesis, 55 interventions were described: 25 with medications, 27 with nutrition and exercise, and 3  
256 with surgical treatment (Table 1).

257

## 258 Data extraction process

259

260 The data extraction from the studies was done, by a team of 13 researchers, with a modified Cochrane  
261 tool for data collection form to obtain detailed information: type of intervention (drug, nutritional  
262 programs, behavioral treatments, use of drugs, surgical interventions or alternative medicine), age of  
263 intervention (childhood, adult), duration of treatments, year of the study development, sample size, groups  
264 of intervention, blindness of the treatment and the size of effects obtained in each study (Cohen's d).  
265 Data extraction was performed in duplicate, and cases of discrepancy were re-analyzed in groups of 4  
266 investigators. When it was necessary, authors were contacted to collect additional information. The main  
267 outcome was related with the reduction of BMI, waist circumference or percentage of body fat and  
268 biochemical parameters such as glucose, total cholesterol, triglycerides, HDL-c, blood pressure, HOMA-  
269 IR and Matsuda. WE used meta-regression to analyze the source of heterogeneity with mean age, mean  
270 BMI, location of the study (represented as latitude of the city of recruitment), sex distribution, and  
271 duration of the study. Adverse effects were also analyzed.

272

273 The quality assessment of the studies was done using the Jadad scale (23) and the risk of bias was  
274 assessed with GRADE checklist (22) with the following assessment guidelines:

275 Low risk studies were treatment with unpredictable allocation: A central office for allocation by phone,  
276 web, and pharmacy. Use of sequentially numbered, sealed, opaque envelopes. The drug containers are  
277 sequentially numbered and identical. Meanwhile high risk is predictable allocation, like staff know the  
278 random sequence in advance. Another high risk of bias was the use of envelopes or packaging without  
279 safeguards or non-random, predictable sequence. The attrition bias can be considered if there was a poor  
280 description on how much data was missing from each group, or the lack of reasons for missing data and  
281 how they were considered in the analysis. We were also interested in whether researchers used intention  
282 to treat analysis, imputation of missing values, or just per protocol analysis.

283

## 284 Statistical analysis

285

286 The obtaining of sample size, means, and standard deviation was done with the data from the included  
287 studies. The summary of contrast was computed with Cohen's-d differences. All models were analyzed  
288 with Restricted maximum likelihood (REML) random effects models, and the pooled effects were  
289 described with 95% confidence intervals. Heterogeneity was assessed with  $I^2$  statistics, and we use  
290 meta-regression to analyze the heterogeneity. These statistical analyses were conducted with Stata 16.0  
291 (StataCorp, College Station TX).

292 The network meta-analysis was computed for studies with medication only, because the designs of  
293 nutrition/behavior studies did not allow us to build nets. The analysis was performed with Stata 16.0 and

## Anti-obesity interventions in Mexican Population

294 CINeMA to define the network geometry, and effects comparisons. We did not have enough samples of  
295 studies to perform a rankogram.  
296

## Anti-obesity interventions in Mexican Population

### 297 Results

298 We collected 634 studies from databases and after duplicate removal identified 64 controlled clinical  
299 trials from PubMed, 27 from Scopus and 15 from Web of Science conducted in Mexico.

### 300 Studies characteristics

301 We included 45 anti-obesity national and multinational collaborative controlled clinical trials involving  
302 overweight and obese Mexican adults (>18 yr) subjected to distinct weight-loss interventions:  
303 pharmaceutical (25 studies), nutrition and behavioral (15 studies), surgical (2 studies), and alternative (3  
304 studies) interventions (Table 1). Overall interventions included exclusively women were 15, men 5, and  
305 both sexes 35.

### 306 Participant cities

307 Considering 45 interventions from 25 studies used in the quantitative analysis, Mexico City had the  
308 highest frequency of studies 38% (n=17), followed by Guadalajara 29% (n=13). The states close to the  
309 U.S. border were three (Nuevo Leon, Tamaulipas and Baja California). The details are described in Table  
310 1.

### 311 Risk of bias and quality

312 We performed a quality assessment at the intervention level. The Jadad mean value for  
313 nutritional/behaviour interventions was 3.6 (min 3, max 5), and for drug treatments was 3.7 (min 2, max  
314 5). The nutrition/behaviour interventions had medium risk of bias (by GRADE) in 95% (n=18/19) and  
315 high risk of bias in 5% (n= 1/19). Physical activity was difficult to blind. The use of medication as  
316 intervention had very low risk of bias in 32% (n=7/22), medium 55% (n=12/22) and high risk in 14%  
317 (n=3/22). No differences in bias were found for intervention including T2D participants (Fisher's exact  
318 test= 0.286).

### 319 Synthesis of results

320 This meta-analysis included data from 2074 participants in nutrition/behaviour interventions and 5086  
321 participants with medication, if we exclude multicentric international studies there were 1525 participants  
322 from studies exclusively made in Mexico. The main outcomes from individual studies are described in  
323 Tables 2 to 4. The forest plots with the pooled analysis are in Figures 3 to 10.

### 324 Nutritional/Behaviour interventions

325 The comparisons between active nutrition/behavior interventions with placebo showed improvement for  
326 BMI [Cohen-d, 95% CI, Figure 3] 0.2 (0.01, 0.38), waist circumference 0.27 (0.01, 0.53, Figure 4),  
327 triglycerides 0.34 (-0.02, 0.71; Figure 5), and systolic blood pressure 0.21 (-0.07, 0.49, Figure 6). The

## Anti-obesity interventions in Mexican Population

328 lowest heterogeneity was for BMI ( $I^2= 41\%$ ) and the highest for triglycerides ( $I^2= 88\%$ ). Only one  
329 intervention with physical activity showed an effect on BMI (Cohen-d of 0.3), increase on HDL-c  
330 (Cohen-d 0.16), but with wide confidence intervals. Most of these studies excluded T2D individuals,  
331 therefore the glucose levels did not show difference between compared groups.

332 The addition of adding CBT (goal setting, problem-solving, and stimulus control) to either a low-fat diet  
333 (21% fat, less than 10% saturated fat, 25% protein, 54% carbohydrates), or a low-carbohydrate diet (27%  
334 protein, 28% fat, 45% carbohydrate) produced significantly greater short-term weight loss compared with  
335 diet alone. The use of antioxidants with flavonoids contained in dark chocolate showed favorable changes  
336 in biochemical parameters (total cholesterol, triglycerides, and LDL-cholesterol level in blood) and  
337 anthropometrical parameters (waist circumference) the pooled analysis with Cohen-d supported  
338 additionally loss of BMI and decrease in systolic blood pressure (Figure 6).

339 Finally, the avoid of sugar-sweetened beverages (SSB) by water substitution showed positive effect on  
340 plasma triglycerides, and systolic blood pressure.

## 341 Drug treatments and T2D status

342 Drug treatment analyzed studies which involved participants with T2D. The size of effect showed  
343 improvement on BMI (Figure 7), waist circumference (Figure 8) and glucose (Figure 9) for non-T2D  
344 individuals compared with patients with T2D. The BMI loss in T2D group had a Cohen-d of 0.24 (0.13,  
345 0.66) compared with non-T2D loss of 0.53 (0.27, 0.80); the waist circumference was Cohen-d 0.22 (0.72,  
346 1.16) compared with non-T2D 0.55 (0.03, 1.07); diastolic blood pressure 0.18 (0.3, 1.42) vs 0.87 (0.33,  
347 2.06), respectively. As expected, the treatment had large effect on glucose lowering for treated T2D  
348 individuals compared with non-T2D (Cohen-d 0.7 compared with 0.26, respectively).

349 Some medications used in Mexico had a large effect on weight reduction (Figures 7 and 8) in participants  
350 without T2D (Cohen-d about 0.9). For instance, the use of DHA (docosahexanoic acid) 470 or 940 mg  
351 combined with EPA (eicosapentanoic acid) 580 or 1160 mg, compared with placebo, and the use of two  
352 different formulations (Formula 1: d-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg,  
353 atropine 0.36 mg, aloin 16.2 mg; and formula 2: d-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin  
354 16.2 mg.) for 6 months compared with placebo. These medications are not approved for treatment of  
355 obesity by FDA, and the formulations are not legally available for purchase in the US, however, reports in  
356 US found thyroid intoxication (70). The effect of liraglutide was between 0.3 to 0.6 including participants  
357 from international samples. Participants with T2D showed the use of phentermine 15 mg and topiramate  
358 100 mg had higher effect compared with phentermine 7.5 mg and placebo. There was no replication for  
359 any of these studies, the Egger test on a random model showed no small study effects on BMI for 18  
360 intervention on nutrition/behavior ( $p=0.43$ ), nor for 19 intervention on medication ( $p=0.22$ ).

361 It is interesting that systolic blood pressure was modified by non-pharmacological treatments, meanwhile,  
362 diastolic blood pressure was modified in non-T2D participants treated with medications (Figure 10).  
363 From the five analyzed studies with medications, three of them included patients with hypertension. The  
364 prevalence of hypertension was between 24 to 42%. The blood pressure decreases with weight loss, the  
365 Trial of Hypertension Prevention had a weight loss intervention arm, resulting in reduction of both,  
366 systolic and diastolic, measurements (71).

## Anti-obesity interventions in Mexican Population

### 367 Study heterogeneity sources

368 The meta regression analyzed the mean age, BMI, months of treatment, comparison with placebo and  
369 geographical location measured by latitude. Those confounders that reached statistical significance for  
370 HDL-c serum levels were the duration of the intervention [b=1.07 (se 0.49) p=0.03] and the comparison  
371 vs placebo [b=4.4 (se 2.1) p=0.04]. The triglyceride serum levels showed effects from the mean age of the  
372 study [b=1.3 (se 0.59) p=0.03] and the geographic location [b= -2.7 (se 1.3) p=0.04]. However, the  
373 geographic location was close related with the type of intervention, for example, studies located close to  
374 the U.S.-Mexico border used physical activity interventions; meanwhile the South regions used  
375 nutritional supplements. The diastolic blood pressure was modified by the BMI [b=-0.49 (se 0.27)  
376 p=0.067] and geographical location [b= -0.9 (se 0.44) p=0.04], however these variables were influenced  
377 by the treatment with liraglutide. [Supplemental Figures 1 and 2]

### 378 Network meta-analysis

379 A network meta-analysis of drug treatments and T2D status was performed for BMI, diastolic blood  
380 pressure (DBP), and glucose. The network meta-analysis included direct comparisons constructed with  
381 connections between treatments, and indirect comparisons using all possible connections between  
382 treatments. All networks had the principles of coherence, transitivity, and consistency. This analysis was  
383 not feasible for nutritional/behavior interventions due to the design and the small number of studies.  
384 Figure 11 illustrates two networks for studies with T2D patients, examining the efficacy of  
385 pharmacological interventions on the studied variables, one network for each comparison between  
386 treatments and placebo (Supplemental figure 3 panel A) and with metformin (Supplemental figure 3 panel  
387 B). These network diagrams provide a graphical representation of how each intervention connects to any  
388 other direct comparisons. Tables 5 (matrix A and B) and Supplemental Tables 1 and 2 detail the complete  
389 matrix of results, in which the comparative effects between drugs are shown in terms of differences in  
390 means standardized.

391 The contrast matrix between pharmacological treatments with placebo showed a decrease on BMI by any  
392 pharmacological intervention, for instance, DHA 470 mg + EPA 580 mg was 0.816 (CI: 0.049, 1.582);  
393 DHA 940 mg + EPA 1160 mg: 0.888 (CI: 0.117, 1.658); Formulation 1: 0.959 (CI: 0.324, 1.593);  
394 Formulation 2: 0.944 (CI: 0.301, 1.588); Liraglutide: 0.451 (CI: 0.141, 0.761). On the other hand, the  
395 status of T2D consistently supported metformin alone and in combinations were the most effective  
396 intervention for reducing BMI compared to insulin: -0.898 (CI: -1.431, -0.366). Regarding glucose, the  
397 intervention with insulin was more effective in reducing serum glucose levels compared to metformin: -  
398 1.506 (CI: -2.084, -0.928); Glimepiride + metformin: -1.332 (CI: -2.083, -0.581) and Glimepiride: -1.332  
399 (CI: -2.077, -0.587). In summary, the interventions with the greatest contribution to the reduction of DBP  
400 were metformin: -0.507 (CI: -0.994, -0.020) compared to Glimepiride + metformin, and Glimepiride: -  
401 0.507 (-0.980, -0.033) compared to Glimepiride + metformin. The monotherapy interventions have better  
402 effectiveness in DBP compared to double therapies.

## Anti-obesity interventions in Mexican Population

403

### 404 Discussion

405 This systematic review and meta-analysis summarize the existing evidence of weight loss as primary or  
406 secondary aims in adult population. Our analysis was limited to randomized clinical studies conducted in  
407 Mexico or from international multicentric studies with Mexican participants involving nutrition, behavior,  
408 medication, or alternative medicine interventions. Some interventions of interest were compared with  
409 another active strategy (medication, behavior, physical activity or any different than placebo), this  
410 strategy can blunt the size of effect of the intervention, because the effect of active comparators in  
411 metabolic and anthropometric variables. We found that all studied interventions were better than placebo,  
412 or better than the selected comparator, and many of the published papers made individual paired contrasts  
413 between final and basal values. However, we decided to contrast treatments and reported the size of  
414 effects by metabolic syndrome component. With this strategy we had the advantage of computing the  
415 effect size over a maneuver the researchers considered the best comparator. The results should be  
416 interpreted considering these control groups defined by the researchers.

### 417 Interventions

418 The 55 analyzed interventions (from 45 studies) were categorized in nutritional/behavior with a total  
419 sample of 1,407 participants; drug interventions in Mexico included 1,134; and multinational  
420 interventions were additional 1,307 participants (Hispanics); surgical procedures were 72 and alternative  
421 treatments 235 individuals. We obtained a total of 4,155 participants from these trials.

422 The nutritional/behavior strategies included supplemental, flavonoids, manipulation of macronutrient  
423 content diets (low fat, low carb, high protein) with caloric restriction, water consumption and physical  
424 activities. Cognitive behavioral therapy (CBT) combined with low calorie diet showed beneficial effects  
425 on BMI and waist circumference; and combined with low fat diet decreased glucose, triglycerides. A  
426 cardioprotective structured hypocaloric diet is more effective than the CBT approach in reducing  
427 metabolic syndrome (59). Daily flavonoid-rich chocolate (70% cocoa) intake improves fasting plasma  
428 glucose levels and insulin resistance parameter (HOMA-IR) and the lipid and glucose metabolism (46).  
429 The physical activity showed benefic but small and non-significant effects for the analyzed variables, due  
430 to the lack of enough sample size. Other systematic reviews focused on physical activity showed  
431 Hispanics had less leisure-time compared with other groups in the U.S., the most common activity was  
432 walking, but the most significant results were those with moderate to vigorous physical activity (72). It  
433 will be crucial to increase legislative policies to build environments that increase available opportunities  
434 for physical activities, particularly for this fast-growing population group.

435 Adherence to diet and exercise programs (45 min-60 min/d, 5 days per week) are part of the  
436 nutritional/behavioral interventions. Other studies reporting that water consumption habit (2-3 L/day) and  
437 partially decreasing sugar-sweetened beverage (SSB) intake of at least 250 kcal/d, with nutritional  
438 counseling was effective in increasing water intake (69), and additionally reduces cardiometabolic risks of  
439 drinking or eating less sugar in the diet promoting health benefits, although we found positive effect on

## Anti-obesity interventions in Mexican Population

440 plasma triglycerides and systolic blood pressure in our analysis, perhaps a consequence of the reduction  
441 of the SSB consumption.

442 The drug treatment with groups of participants with T2D, showed small effect size on improvement on  
443 BMI, waist circumference and triglycerides compared with larger effects for non-T2D. The orlistat group  
444 in T2D showed weight loss (BMI and waist circumference) lower level of glucose, triglycerides, and  
445 systolic blood pressure. Comparing these findings with other studies made in Mexican Americans living  
446 in the border shows the difficulty of losing weight with programs on self-management education, but the  
447 HbA1c improved (73). No medication will overcome unhealthy lifestyles.

448 Medication showed a larger size of effects on BMI for combined formulations like orlistat, phentermine  
449 with topiramate, both approved by regulatory agencies. Other formulations like the combination of  
450 triiodothyronine with phentermine (non-approved by FDA but approved by COFEPRIS – Federal  
451 Committee for Protection from Sanitary Risks), and combination of DHA and EPA showed effect on  
452 BMI. The authors of the formulations did not show the result on serum glucose neither reported any  
453 adverse effect. There was no replication for any of these treatments. We found a couple of sibutramine  
454 trials. This is a retired medication because the cardiovascular risk was greater than the benefits (74),  
455 specially for the difficulty to identify patients with silent cardiovascular disease (75).

456 Surgical intervention is the most effective treatment for patients with morbid obesity.(76) The percentage  
457 of body weight loss with this intervention ranges between 33 and 77% in a period of 24 months, thus  
458 demonstrating its effectiveness (77, 78). However, in our surgical papers, no significant differences were  
459 found in the percentage of weight loss, this due to the fact that both the intervention group and the control  
460 group had equivalent surgeries (79). One of the studies compared banded versus unbanded laparoscopic  
461 roux-en-Y gastric bypass and follow up weight changes for 24 months,(67) in a second analysis no  
462 differences were found between these procedures after five years of follow up (66).

463

## 464 Risk of bias

465 In general, many of the studied interventions are challenging to blind for obvious reasons. For example, a  
466 comparison of nutritional interventions vs. exercise or CBT cannot be blind. However, there is a  
467 possibility to blind the evaluators, but no studies explicitly describe this strategy. We found that  
468 heterogeneity of the results were partially attributable to basal differences between contrasting groups, for  
469 example in the study of Rosado et al.,(51) the diastolic and systolic blood pressure were significantly  
470 different between the studied low fat milk groups compared with controls. Some surgical studies for  
471 weight loss made in the Instituto de Nutricion Salvador Zubiran in Mexico City blinded the abdominal  
472 wall for patients and evaluators when they compared the open abdominal approach versus the  
473 laparoscopic method. The risk of bias can be lessened but still can compromise the results of the studies.  
474 The difficulty in addressing nutritional or behavioral interventions is manifest in studies analyzing  
475 racial/ethnic disparities. Multilevel church-based interventions considering socio-ecological influence  
476 showed a greater impact if they consider program interventions tailored to specific communities.

## 477 *Limitations*

## Anti-obesity interventions in Mexican Population

478 The most important limitations are the lack of replication studies with the same medications, and the  
479 small sample size for most of the studies. There was wide variety in the criteria for selection of the  
480 participants (i.e.: some studies had too specific eligibility criteria for sex, age and BMI compared with  
481 other studies with wide range of options), and, despite similar genetic background, the participants live in  
482 sites embedded in cultural diversity (i.e.: Mexico City's environment problems differ from those in States  
483 close to the U.S.-Mexico border). We address a broad question regarding the metabolic syndrome  
484 components with important heterogeneity of the studies. We addressed this problem using meta-  
485 regression to statistically weight the main confounders across studies and the use of a network meta-  
486 analysis to compute the magnitude of contrasts between treatment effects. Due to these limitations the  
487 obtention of unstable coefficients is possible, therefore, the analysis should be repeated in the future with  
488 a greater number of studies.

489 The small sample sizes from many of the included studies resulted in low statistical power for contrasting  
490 between treatment, and the lack of replication studies increased the standard error for the analysis. The  
491 new medications approved by FDA have been tested scarcely in Mexican population. About 44% of the  
492 studies were performed in the limit time of placebo effects (about 12 weeks), but those with more time  
493 showed effects on the HDL cholesterol levels.

494 Future new and replication studies should consider larger periods for treatments to reduce placebo effects.  
495 Future reviews and meta-analysis should analyze anti-obesity interventions in children and adolescents as  
496 well old age populations. These suggestions agree with the Healthy People 2030 recommendation on  
497 study effective strategies to diminish obesity in children and adolescents (80).

498 The Mexican states conducted research in anti-obesity interventions were ten from 32 states. The U.S.-  
499 Mexico border has sister states: California-Baja California, Arizona-Sonora, New Mexico-Chihuahua,  
500 Texas with Chihuahua, Coahuila, Nuevo Leon and Tamaulipas. The Binational initiative should improve  
501 the collaborative studies in the U.S.-Mexico border to address interventions in this population. The  
502 programs from this initiative addresses environmental protection, communication committees in  
503 particular communities (81). The U.S.-Mexico Border Health Commission has agreements with the  
504 Secretary of Health from both countries, and this agency supports initiatives in health security (82). The  
505 programs include prevention and wellness using guidelines for eating healthy, physical activity, and of  
506 drug misuse and abuse prevention.

507

## 508 Conclusions

509 Since 1996, anti-obesity interventions have been conducted in Mexico in randomized controlled clinical  
510 studies, mainly focused on pharmaceutical, nutritional, or physical activity interventions. Adult  
511 participants included in these studies were predominantly from the central and northern Mexican states,  
512 with a clear absence from the costal and southern states. Anti-obesity studies in the Mexican population  
513 include small samples and reduced time for interventions. A strategy to improve the statistical power for  
514 the studies is to conduct multicentric studies, and a compromise for the State or private industries to  
515 provide sufficient financial resources.



## Anti-obesity interventions in Mexican Population

516 A national web of research is feasible for answering relevant questions regarding anti-obesity  
517 interventions and its metabolic consequences. It is clear that not all metabolic syndrome components have  
518 the same response to the intervention. The inclusion of Mexican Americans and Mexican immigrants  
519 living in the U.S. would be desirable to clarify the importance of different techniques to tackle this  
520 problem.

### 521 **Acknowledgement**

522 We thanks Dr. Victoria Valles from the National Institute of Medical Sciences and Nutrition Dr. Salvador  
523 Zubiran (INCMNSZ) for the share of invaluable experience about the ENEC-93. Last, we would like to  
524 pay our gratitude and our respects to Dr. Gonzalez-Barranco. He was a pioneer in obesity research since  
525 1970s, Dr. Gonzalez-Barranco passed away in December of 2020.

526

### 527 **Funding**

528

529

530

## Anti-obesity interventions in Mexican Population

531

## 532 References

533

534

- 535 1. Finegold A. *Dramatic Renditions: Battle Murals and the Struggle for Elite Legitimacy in*  
536 *Epiclassic Mesoamerica*: Columbia University; 2012.
- 537 2. DeSmet P. *Figurines with distended abdomen from ancient Western Mexico* [2020 January 5th,  
538 2021]. Available from: [https://www.academia.edu/Documents/in/Pre-Columbian\\_Art](https://www.academia.edu/Documents/in/Pre-Columbian_Art)
- 539 3. Christopoulou-Aletra H, Papavramidou N. Methods used by the hippocratic physicians for weight  
540 reduction. *World J Surg*. 2004;28(5):513-7.
- 541 4. Eknoyan G. A history of obesity, or how what was good became ugly and then bad. *Adv Chronic*  
542 *Kidney Dis*. 2006;13(4):421-7.
- 543 5. Atwater WOB, F. G. . *Experiments on the metabolism of matter and energy in the human body*.  
544 In: USDA Office of Experiment Stations B, editor. Washington DC: Government Printing Office; 1902.  
545 p. 150.
- 546 6. Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. *Obes Res*.  
547 1996;4(2):201-3.
- 548 7. Services USDoHaH. *Healthy People 2020: United States Department of Health and Human*  
549 *Services*, Washington, DC; 2010 [Available from: [https://www.healthypeople.gov/2020/About-Healthy-](https://www.healthypeople.gov/2020/About-Healthy-People)  
550 *People*].
- 551 8. Komaroff M. For Researchers on Obesity: Historical Review of Extra Body Weight Definitions. *J*  
552 *Obes*. 2016;2016:2460285.
- 553 9. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. *StatPearls*. Treasure Island  
554 (FL)2020.
- 555 10. Rtveldze K, Marsh T, Barquera S, Sanchez Romero LM, Levy D, Melendez G, et al. Obesity  
556 prevalence in Mexico: impact on health and economic burden. *Public Health Nutr*. 2014;17(1):233-9.
- 557 11. Kondrup J. Basic concepts in nutrition: Energy and protein balance. *e-SPEN, the European e-*  
558 *Journal of Clinical Nutrition and Metabolism* [Internet]. 2008; 3:[e117-e20 pp.].
- 559 12. Lopez-Alvarenga JC, Montesinos-Cabrera RA, Velazquez-Alva C, Gonzalez-Barranco J. Short  
560 stature is related to high body fat composition despite body mass index in a Mexican population. *Arch*  
561 *Med Res*. 2003;34(2):137-40.
- 562 13. Castro-Porras LV, Rojas-Russell ME, Aedo-Santos A, Wynne-Bannister EG, Lopez-Cervantes  
563 M. Stature in adults as an indicator of socioeconomic inequalities in Mexico. *Rev Panam Salud Publica*.  
564 2018;42:e29.
- 565 14. Salud Sd. NORMA OFICIAL MEXICANA NOM-174-SSA1-1998, PARA EL MANEJO  
566 INTEGRAL DE LA OBESIDAD. 1998.
- 567 15. Maldonado LE, Albrecht SS. Does the Immigrant Advantage in Overweight/Obesity Persist over  
568 Time in Mexican American Youth? NHANES 1988-1994 to 2005-2014. *Obesity (Silver Spring)*.  
569 2018;26(6):1057-62.
- 570 16. Yoshida Y, Scribner R, Chen L, Broyles S, Phillippi S, Tseng TS. Role of Age and Acculturation  
571 in Diet Quality Among Mexican Americans - Findings From the National Health and Nutrition  
572 Examination Survey, 1999-2012. *Prev Chronic Dis*. 2017;14:E59.
- 573 17. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in  
574 humans. *Clin Pharmacokinet*. 2010;49(2):71-87.
- 575 18. Initiative NOE. *The practical guide. Identification, evaluation, and treatment of overweight and*  
576 *obesity in adults*. NIH publication Number 00-4084. 2000.
- 577 19. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European Guidelines for  
578 Obesity Management in Adults. *Obes Facts*. 2015;8(6):402-24.

## Anti-obesity interventions in Mexican Population

- 579 20. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al.  
580 Pharmacological management of obesity: an endocrine Society clinical practice guideline. *J Clin*  
581 *Endocrinol Metab.* 2015;100(2):342-62.
- 582 21. Ehara T. Mexico and its obesity epidemic. *Global Food Cultures* [Internet]. 2018. Available from:  
583 <https://wp.nyu.edu/steinhardt-gfcmexico2018/2018/04/11/mexico-and-its-obesity-epidemic/>.
- 584 22. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to  
585 aid consistency and reproducibility of GRADE assessments: development and pilot validation. *Syst Rev.*  
586 2014;3:82.
- 587 23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the  
588 quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials.* 1996;17(1):1-  
589 12.
- 590 24. Gonzalez-Heredia T, Hernandez-Corona DM, Gonzalez-Ortiz M, Martinez-Abundis E. Effect of  
591 Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance.  
592 *Diabetes Technol Ther.* 2017;19(8):471-5.
- 593 25. Gonzalez-Ortiz M, Martinez-Abundis E, Hernandez-Corona DM, Ramirez-Rodriguez AM. Effect  
594 of tadalafil administration on insulin secretion and insulin sensitivity in obese men. *Acta Clin Belg.*  
595 2017;72(5):326-30.
- 596 26. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of  
597 liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with  
598 prediabetes: a randomised, double-blind trial. *Lancet.* 2017;389(10077):1399-409.
- 599 27. O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, et al. Effects of  
600 Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hispanic Populations: Subgroup  
601 Analysis from Scale Randomized Trials. *Endocr Pract.* 2016;22(11):1277-87.
- 602 28. Sanchez-Rodriguez MA, Zacarias-Flores M, Castrejon-Delgado L, Ruiz-Rodriguez AK,  
603 Mendoza-Nunez VM. Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with  
604 Metabolic Syndrome. *Int J Mol Sci.* 2016;17(9).
- 605 29. Sanchez-Munoz V, Salas-Romero R, Del Villar-Morales A, Martinez-Coria E, Pegueros-Perez A,  
606 Franco-Sanchez JG. [Decrease of liver fat content by aerobic exercise or metformin therapy in overweight  
607 or obese women]. *Rev Invest Clin.* 2013;65(4):307-17.
- 608 30. Gonzalez-Acevedo O, Hernandez-Sierra JF, Salazar-Martinez A, Mandeville PB, Valadez-  
609 Castillo FJ, De La Cruz-Mendoza E, et al. [Effect of Omega 3 fatty acids on body female obese  
610 composition]. *Arch Latinoam Nutr.* 2013;63(3):224-31.
- 611 31. Martínez-Abundis E, Valera-Gonzalez I, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of  
612 metformin and sibutramine on insulin sensitivity and adiposity in obese patients. *Obesity and*  
613 *Metabolism.* 2010;6:100-4.
- 614 32. Meaney E, Vela A, Samaniego V, Meaney A, Asbun J, Zempoalteca JC, et al. Metformin, arterial  
615 function, intima-media thickness and nitrooxidation in metabolic syndrome: the mefisto study. *Clin Exp*  
616 *Pharmacol Physiol.* 2008;35(8):895-903.
- 617 33. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala  
618 MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.  
619 *Cardiovasc Drugs Ther.* 2006;20(2):143-6.
- 620 34. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, et al. X-PERT: weight reduction  
621 with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to  
622 treatment predicts weight maintenance. *Diabetes Obes Metab.* 2005;7(6):699-708.
- 623 35. Zaragoza RM, Lonngi, G., Ortiz, R.A., Huerta, D.R. Comparison of two formulations of d-  
624 norpseudoephedrine and placebo in obese patients treated during six months [Comparación de dos  
625 formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses]. *Med*  
626 *Int Mex.* 2001;17:260-71.
- 627 36. Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine  
628 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. *Obes Res.*  
629 2000;8(1):71-82.

## Anti-obesity interventions in Mexican Population

- 630 37. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine  
631 for the treatment of patients suffering essential obesity. *Int J Obes Relat Metab Disord.* 2000;24(2):144-  
632 50.
- 633 38. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study  
634 clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after  
635 treatment cross-over. *Int J Obes Relat Metab Disord.* 2001;25(5):741-7.
- 636 39. Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Gonzalez-  
637 Lopez R, Santiago-Hernandez NJ. Effect of diacerein on insulin secretion and metabolic control in drug-  
638 naive patients with type 2 diabetes: a randomized clinical trial. *Diabetes Care.* 2011;34(7):1591-4.
- 639 40. Fanghanel G, Silva U, Sanchez-Reyes L, Sisson D, Sotres D, Torres EM. Effects of metformin on  
640 fibrinogen levels in obese patients with type 2 diabetes. *Rev Invest Clin.* 1998;50(5):389-94.
- 641 41. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin's effects on  
642 glucose and lipid metabolism in patients with secondary failure to sulfonylureas. *Diabetes Care.*  
643 1996;19(11):1185-9.
- 644 42. Villar MM, Martinez-Abundis E, Preciado-Marquez RO, Gonzalez-Ortiz M. Effect of diacerein  
645 as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. *Arch*  
646 *Endocrinol Metab.* 2017;61(2):188-92.
- 647 43. A. H-B. Phentermine and topiramato vs phentermine plus placebo in patients with overweight or  
648 obesity class I or II [Fentermina y topiramato contra fentermina más placebo en pacientes con sobrepeso u  
649 obesidad clase I o II]. *Med Int Mex.* 2015;31:125-36.
- 650 44. Gonzalez-Ortiz M, Martinez-Abundis E, Grupo para el Tratamiento de la Diabetes Mellitus con  
651 C. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in  
652 patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. *Rev*  
653 *Invest Clin.* 2004;56(3):327-33.
- 654 45. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial  
655 of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. *Diabetes Obes*  
656 *Metab.* 2003;5(3):180-8.
- 657 46. Leyva-Soto A, Chavez-Santoscoy RA, Lara-Jacobo LR, Chavez-Santoscoy AV, Gonzalez-  
658 Cobian LN. Daily Consumption of Chocolate Rich in Flavonoids Decreases Cellular Genotoxicity and  
659 Improves Biochemical Parameters of Lipid and Glucose Metabolism. *Molecules.* 2018;23(9).
- 660 47. Padilla-Camberos E, Barragan-Alvarez CP, Diaz-Martinez NE, Rathod V, Flores-Fernandez JM.  
661 Effects of Agave fructans (Agave tequilana Weber var. azul) on Body Fat and Serum Lipids in Obesity.  
662 *Plant Foods Hum Nutr.* 2018;73(1):34-9.
- 663 48. Hernandez-Corona DM, Martinez-Abundis E, Gonzalez-Ortiz M. Effect of fucoidan  
664 administration on insulin secretion and insulin resistance in overweight or obese adults. *J Med Food.*  
665 2014;17(7):830-2.
- 666 49. Martinez-Abundis E, Gonzalez-Ortiz M, Mercado-Sesma AR, Reynoso-von-Drateln C, Moreno-  
667 Andrade A. Effect of avocado soybean unsaponifiables on insulin secretion and insulin sensitivity in  
668 patients with obesity. *Obes Facts.* 2013;6(5):443-8.
- 669 50. Tovar AR, Caamano Mdel C, Garcia-Padilla S, Garcia OP, Duarte MA, Rosado JL. The inclusion  
670 of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach  
671 recommended intakes of micronutrients and decrease plasma triglycerides: a randomized clinical trial in  
672 obese Mexican women. *Nutr J.* 2012;11:44.
- 673 51. Rosado JL, Garcia OP, Ronquillo D, Hervert-Hernandez D, Caamano Mdel C, Martinez G, et al.  
674 Intake of milk with added micronutrients increases the effectiveness of an energy-restricted diet to reduce  
675 body weight: a randomized controlled clinical trial in Mexican women. *J Am Diet Assoc.*  
676 2011;111(10):1507-16.
- 677 52. Hernandez-Gonzalez SO, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA.  
678 Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique  
679 in obese subjects. *Nutr Res.* 2010;30(6):392-5.

## Anti-obesity interventions in Mexican Population

- 680 53. Ble-Castillo JL, Aparicio-Trapala MA, Francisco-Luria MU, Cordova-Uscanga R, Rodriguez-  
681 Hernandez A, Mendez JD, et al. Effects of native banana starch supplementation on body weight and  
682 insulin sensitivity in obese type 2 diabetics. *Int J Environ Res Public Health*. 2010;7(5):1953-62.
- 683 54. Gomez-Garcia A, Hernandez-Salazar E, Gonzalez-Ortiz M, Martinez-Abundis E. [Effect of oral  
684 zinc administration on insulin sensitivity, leptin and androgens in obese males]. *Rev Med Chil*.  
685 2006;134(3):279-84.
- 686 55. Campos-Nonato I, Hernandez L, Barquera S. Effect of a High-Protein Diet versus Standard-  
687 Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial. *Obes*  
688 *Facts*. 2017;10(3):238-51.
- 689 56. de Jesus Romero-Prado MM, Curiel-Beltran JA, Miramontes-Espino MV, Cardona-Munoz EG,  
690 Rios-Arellano A, Balam-Salazar LB. Dietary flavonoids added to pharmacological antihypertensive  
691 therapy are effective in improving blood pressure. *Basic Clin Pharmacol Toxicol*. 2015;117(1):57-64.
- 692 57. Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, Guerrero-Romero F.  
693 Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of  
694 type of diet. *Ann Hepatol*. 2011;10(4):486-92.
- 695 58. Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Perez-Mendez O, et al. The effect of two  
696 energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and  
697 metabolic syndrome parameters: a randomized controlled trial. *Metabolism*. 2011;60(11):1551-9.
- 698 59. Perichart-Perera O, Balas-Nakash M, Munoz-Manrique C, Legorreta-Legorreta J, Rodriguez-  
699 Cano A, Mier-Cabrera J, et al. Structured hypocaloric diet is more effective than behavioral therapy in  
700 reducing metabolic syndrome in Mexican postmenopausal women: a randomized controlled trial.  
701 *Menopause*. 2014;21(7):711-20.
- 702 60. Macias-Cervantes MH, Rodriguez-Soto JM, Uribarri J, Diaz-Cisneros FJ, Cai W, Garay-Sevilla  
703 ME. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in  
704 adult overweight men. *Nutrition*. 2015;31(3):446-51.
- 705 61. Rodriguez-Hernandez H, Morales-Amaya UA, Rosales-Valdez R, Rivera-Hinojosa F, Rodriguez-  
706 Moran M, Guerrero-Romero F. Adding cognitive behavioural treatment to either low-carbohydrate or  
707 low-fat diets: differential short-term effects. *Br J Nutr*. 2009;102(12):1847-53.
- 708 62. Moran S, Uribe M, Prado ME, de la Mora G, Munoz RM, Perez MF, et al. [Effects of fiber  
709 administration in the prevention of gallstones in obese patients on a reducing diet. A clinical trial]. *Rev*  
710 *Gastroenterol Mex*. 1997;62(4):266-72.
- 711 63. Garcia-Vivas JM, Galaviz-Hernandez C, Becerril-Chavez F, Lozano-Rodriguez F, Zamorano-  
712 Carrillo A, Lopez-Camarillo C, et al. Acupoint catgut embedding therapy with moxibustion reduces the  
713 risk of diabetes in obese women. *J Res Med Sci*. 2014;19(7):610-6.
- 714 64. Hernandez-Lepe MA, Wall-Medrano A, Lopez-Diaz JA, Juarez-Oropeza MA, Hernandez-Torres  
715 RP, Ramos-Jimenez A. Hypolipidemic Effect of *Arthrospira* (*Spirulina*) *maxima* Supplementation and a  
716 Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and  
717 Crossover Controlled Trial. *Mar Drugs*. 2019;17(5).
- 718 65. Alvarado-Reynoso B, Ambriz-Tututi M. Effects of repetitive transcranial magnetic stimulation in  
719 combination with a low-carbohydrate diet in overweight or obese patients. A randomized controlled trial.  
720 *Obesity Medicine*. 2019;14:100095.
- 721 66. Zarate X, Arceo-Olaiz R, Montalvo Hernandez J, Garcia-Garcia E, Pablo Pantoja J, Herrera MF.  
722 Long-term results of a randomized trial comparing banded versus standard laparoscopic Roux-en-Y  
723 gastric bypass. *Surg Obes Relat Dis*. 2013;9(3):395-7.
- 724 67. Arceo-Olaiz R, Espana-Gomez MN, Montalvo-Hernandez J, Velazquez-Fernandez D, Pantoja JP,  
725 Herrera MF. Maximal weight loss after banded and unbanded laparoscopic Roux-en-Y gastric bypass: a  
726 randomized controlled trial. *Surg Obes Relat Dis*. 2008;4(4):507-11.
- 727 68. Robles-Cervantes JA, Martinez-Abundis E, Gonzalez-Ortiz M, Cardenas-Camarena L,  
728 Hernandez-Salazar E, Olvera-Ozuna R. Behavior of insulin sensitivity and its relation to leptin and tumor  
729 necrosis factor-alpha in obese women undergoing liposuction: 6-month follow-up. *Obes Surg*.  
730 2007;17(9):1242-7.

## Anti-obesity interventions in Mexican Population

- 731 69. Hernandez-Cordero S, Barquera S, Rodriguez-Ramirez S, Villanueva-Borbolla MA, Gonzalez de  
732 Cossio T, Dommarco JR, et al. Substituting water for sugar-sweetened beverages reduces circulating  
733 triglycerides and the prevalence of metabolic syndrome in obese but not in overweight Mexican women  
734 in a randomized controlled trial. *J Nutr*. 2014;144(11):1742-52.
- 735 70. Cantrell L. Redotex(R) revisited: intentional overdose with an illegal weight loss product. *J*  
736 *Emerg Med*. 2012;43(2):e147-8.
- 737 71. The effects of nonpharmacologic interventions on blood pressure of persons with high normal  
738 levels. Results of the Trials of Hypertension Prevention, Phase I. *JAMA*. 1992;267(9):1213-20.
- 739 72. Loya JC. Systematic Review of Physical Activity Interventions in Hispanic Adults. *Hisp Health*  
740 *Care Int*. 2018;16(4):174-88.
- 741 73. Brown SA, Garcia AA, Kouzekanani K, Hanis CL. Culturally competent diabetes self-  
742 management education for Mexican Americans: the Starr County border health initiative. *Diabetes Care*.  
743 2002;25(2):259-68.
- 744 74. Williams G. Withdrawal of sibutramine in Europe. *BMJ*. 2010;340:c824.
- 745 75. Curfman GD, Morrissey S, Drazen JM. Sibutramine--another flawed diet pill. *N Engl J Med*.  
746 2010;363(10):972-4.
- 747 76. Peterli R, Wolnerhanssen BK, Peters T, Vetter D, Kroll D, Borbely Y, et al. Effect of  
748 Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients  
749 With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. *JAMA*. 2018;319(3):255-65.
- 750 77. Buchwald H, Buchwald JN, McGlennon TW. Systematic review and meta-analysis of medium-  
751 term outcomes after banded Roux-en-Y gastric bypass. *Obes Surg*. 2014;24(9):1536-51.
- 752 78. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. *N*  
753 *Engl J Med*. 2017;376(15):1492.
- 754 79. Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight  
755 loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.  
756 *Surg Obes Relat Dis*. 2017;13(3):491-500.
- 757 80. Promotion OoDPaH. Overweight and Obesity 2020 [January 11, 2021]. Available from:  
758 <https://health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity>.
- 759 81. Agency USEP. What is Border 2020? 2020 [updated September 1, 2020; January 4, 2021].  
760 Available from: <https://www.epa.gov/usmexicoborder/what-border-2020>.
- 761 82. Services USDoHH. U.S.-Mexico Border Health Commission 2020 [Available from:  
762 [https://www.hhs.gov/about/agencies/oga/about-oga/what-we-do/international-relations-](https://www.hhs.gov/about/agencies/oga/about-oga/what-we-do/international-relations-division/americas/border-health-commission/index.html)  
763 [division/americas/border-health-commission/index.html](https://www.hhs.gov/about/agencies/oga/about-oga/what-we-do/international-relations-division/americas/border-health-commission/index.html).  
764  
765

## Anti-obesity interventions in Mexican Population

766 Figure Legends

767

768 Figure 1. Height measurement standing up, sitting and the lower body segment. From North to South the  
769 height is lower at expenses to the lower segment of the body ( $p < 0.0001$  adjusted by Bonferroni for all  
770 regions). The sitting height reflects the upper segment body and shows small differences between regions.  
771 Mean and standard deviations. Data obtained from the ENEC 1993. CDMX: Mexico City, Sitting: sitting  
772 height, Lower: Lower segment of the body (Height-sitting height).

773

774 Figure 2. Procedure of the study. The flowchart shows the processes of collection, screening, quality  
775 assessment data extraction and analysis.

776

777 Figure 3. Pooled analysis of weighted size of effect by Cohen-d in BMI loss with nutritional and behavior  
778 interventions. The analysis was stratified by placebo or active comparator. LFDT: Low fat diet, LCD:  
779 Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark  
780 chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, WEP: Water and Education  
781 Provision, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal replacement, AntiBP:  
782 Antihypertensive medication. REML: Restricted maximum likelihood.

783

784 Figure 4. Pooled analysis of weighted size of effect by Cohen-d in waist circumference with nutritional  
785 and behavior interventions. The analysis was stratified by placebo or active comparator. LFDT: Low fat  
786 diet, LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark  
787 Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, LFM: Low fat  
788 milk, Micronut: Micronutrients, PMR: Partial meal replacement. REML: Restricted maximum likelihood.

789

790 Figure 5. Pooled analysis of weighted size of effect by Cohen-d in triglycerides serum concentration with  
791 nutritional and behavior interventions. The analysis was stratified by placebo or active comparator.  
792 LFDT: Low fat diet, LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical  
793 activity, Dark Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet,  
794 WEP: Water and Education Provision, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal  
795 replacement, AntiBP: Antihypertensive medication. REML: Restricted maximum likelihood.

796

797 Figure 6. Pooled analysis of weighted size of effect by Cohen-d in systolic blood pressure with nutritional  
798 and behavior interventions. The analysis was stratified by placebo or active comparator. LCD: Low  
799 carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark  
800 chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, WEP: Water and Education  
801 Provision, LFM: Low fat milk, Micronut: Micronutrients, AntiBP: Antihypertensive medication. REML:  
802 Restricted maximum likelihood.

803 Figure 7. Pooled analysis of weighted size of effect by Cohen-d in BMI loss with drug (medication)  
804 treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in the text, they  
805 are not approved by FDA. Met: Merformin, Sibut: Sibutramine, DHA: Docosahexaenoic acid, EPA:  
806 Eicosapentanoic acid, Orlist: Orlistat, Glim: Glimperide, Phent: Phentermine, Top: Topiramate. REML:  
807 Restricted maximum likelihood.

808

## Anti-obesity interventions in Mexican Population

809 Figure 8. Pooled analysis of weighted size of effect by Cohen-d in waist circumference with drug  
810 (medication) treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in  
811 the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, DHA: Docosahexaenoic  
812 acid, EPA: Eicosapentanoic acid, Orlist: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top:  
813 Topiramate. REML: Restricted maximum likelihood.

814  
815 Figure 9. Pooled analysis of weighted size of effect by Cohen-d in glucose serum concentration with drug  
816 (medication) treatment. The analysis was stratified by T2D status. Met: Merformin, Orlist: Orlistat, Glim:  
817 Glimepiride, Phent: Phentermine, Top: Topiramate. REML: Restricted maximum likelihood.

818  
819 Figure 10. Pooled analysis of weighted size of effect by Cohen-d in diastolic blood pressure with drug  
820 (medication) treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in  
821 the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlist: Orlistat, Glim:  
822 Glimepiride, Phent: Phentermine, Top: Topiramate. REML: Restricted maximum likelihood.

823  
824 Supplemental Figure 1. Meta regression of medication mean difference effects on HDL-C (upper panel)  
825 and triglycerides (lower panel) concentrations, adjusted by mean age, BMI, duration of treatment  
826 (months), geographical latitude and use of placebo or active comparator. The grey zone represents the  
827 95%CI of the regression. Liraglutide was used in the highest obesity and geographical sites at North. The  
828 Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut:  
829 Sibutramine, Orlist: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate.


830  
831 Supplemental Figure 2. Meta regression of medication mean difference effects on diastolic blood pressure  
832 adjusted by mean age, BMI, duration of treatment (months), geographical latitude and use of placebo or  
833 active comparator. The upper panel shows the effect of BMI and the lower panel the geographical  
834 location. The grey zone represents the 95%CI of the regression. Liraglutide was used in the highest  
835 obesity and geographical sites at North. The Form1 and Form2 are described in the text, they are not  
836 approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlist: Orlistat, Glim: Glimepiride, Phent:  
837 Phentermine, Top: Topiramate.

838  
839 Supplemental figure 3. Network meta-analysis of the studies examining the efficacy of drug treatments in  
840 patients with obesity in (A) BMI in non-diabetic patients compared to placebo, (B) BMI in patients with  
841 diabetes compared to metformin. The colors of edges and nodes refer to the risk of bias: low (green),  
842 moderate (yellow), and high (red). The dosage of DHA and EPA are in mg per day. Met: Metformin.  
843 Diac+Met: Diacerein + Metformin. The Form1 and Form2 are described in the text, they are not approved  
844 by FDA. Plc: Placebo.

845  
846  
847  
848




## Anti-obesity interventions in Mexican Population



849  
850 Figure 1  
851


## Anti-obesity interventions in Mexican Population



852  
853  
854

Figure 2.

## Anti-obesity interventions in Mexican Population




855 Random-effects REML model

856 Figure 3.


857

## Anti-obesity interventions in Mexican Population



858 Random-effects REML model  
 859 Figure 4.  
 860

## Anti-obesity interventions in Mexican Population




861 Random-effects REML model

862 Figure 5.

863

## Anti-obesity interventions in Mexican Population




864 Random-effects REML model

865 Figure 6.

866

## Anti-obesity interventions in Mexican Population




867 Random-effects REML model

868 Figure 7.

869

## Anti-obesity interventions in Mexican Population




870 Random-effects REML model

871 Figure 8.

872



## Anti-obesity interventions in Mexican Population




873 Random-effects REML model

874 Figure 9.

875

## Anti-obesity interventions in Mexican Population



876 Random-effects REML model

877 Figure 10.

878

## Anti-obesity interventions in Mexican Population

879 Table 1. Characteristics of the analyzed interventions (n=58). Duration of study: («) < 3 months,  
 880 (\*) ≥ 3 months to 9 months, (§) ≥ 12 months. † Frequency from 45 analyzed studies.  
 881

Category	N	%	References
<b>Study Design</b>			
<b>A. Drugs</b>	<b>28</b>	<b>48.3</b>	
A1. Non- diabetic patients	17 (* § «)	29.3	(24-38)
A2. Diabetic patients	11 (*)	19.0	(39-45)
<b>B. Nutrition and exercise</b>	<b>28</b>	<b>48.3</b>	
B1. Food and supplements	11 (* «)	19.0	(31, 46-54)
B2. Diet	6 (* «)	10.3	(50, 55-58)
B3. Behavioral	1 (*)	1.7	(59)
B4. Exercise	1 (*)	1.7	(60)
B5. Multi-component	7 (* «)	12.1	(50, 51, 60-62)
B6. Alternative	2 («)	3.4	(63-65)
<b>C. Surgery</b>	<b>2</b>	<b>3.4</b>	
C1. Cx	1 (§)	1.7	(67)
C2. Cx-diet	1 (*)	1.7	(68)
<b>Gender †</b>			
Male	5	11.1	(25, 28, 54, 60, 64)
Female	9	20	(29, 30, 50, 51, 57, 59, 61, 63, 68)
Both	31	68.9	(24, 26, 27, 31-49, 52-56, 58, 59, 62, 65, 67, 69)
<b>Age †</b>			
Youth (18-35)	11	24.4	(24, 46, 47, 49-51, 54, 58, 68)
Young adults (36-45)	21	46.7	(25, 27-29, 33-37, 39, 42, 43, 48, 52, 53, 56, 60-63, 69)
Older adults (46 or more)	13	28.9	(24, 26, 40-42, 44, 45, 57, 59, 65, 67)
<b>City †</b>			
México City	17	37.8	(29, 32, 35-38, 40, 41, 43, 45, 54, 59, 62, 63, 65, 67)
Guadalajara	13	28.9	(24, 25, 31, 33, 39, 42, 44, 47-49, 52, 56, 68)
Cd. Madero	3	6.7	(26, 27, 58)
Cuernavaca	2	4.4	(55, 69)
Durango	2	4.4	(57, 61)

## Anti-obesity interventions in Mexican Population

Querétaro	2	4.4	(50, 51)
Tijuana	2	4.4	(46, 64)
León	1	2.2	(60)
Monterrey	1	2.2	(34)
San Luis Potosí	1	2.2	(30)
Villahermosa	1	2.2	(53)

882

883

884

885 Table 2. Descriptive characteristics and assessment of Nutrition/behavior interventions.  
886

Nutritional and Behavioral Intervention							
Author State Year	Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Moran <sup>62</sup> Mexico City 1997	Male and Female Intervention: 39 ± 15; Control: 38 ± 10 years old. BMI ≥30 Kg/m <sup>2</sup>	36	<b>Intervention:</b> diet + 750 mg ursodeoxycholic acid (AUD) + fiber placebo <b>Control:</b> diet + 15g Plantago psyllium (pp) + AUD placebo	<b>Intervention:</b> 18, 18 <b>Control:</b> 18, 18	2 months	<b>Primary:</b> prevention of gallstone disease (GD) in obese subjects undergoing a weight-reduction diet. Cholesterol crystals in duodenal bilis were used as surrogate of GD risk.	<b>Yes:</b> Treated individuals had less presence of cholesterol crystals.
Rodriguez-Hernandez <sup>61</sup> Durango 2009	Female 45.4 ± 10.4 years old BMI ≥30 Kg/m <sup>2</sup>	105	<b>Intervention:</b> Cognitive behavioral treatment + Low carb diet or low- fat diet <b>Control:</b> Non cognitive behavioral treatment	<b>Intervention:</b> 55, 52 <b>Control:</b> 50, 50	6 months	<b>Primary:</b> weight loss. <b>Secondary:</b> Depression and anxiety, fasting glucose and triglycerides.	<b>Yes:</b> CBT-LF had significant differences were observed in waist circumference, weight, and BMI in the and significantly decreased body fat, weight, BMI and triglycerides compared with C-LF group.
Ble-Castillo <sup>53</sup> Tabasco 2010	Male and Female 51.7 ± 5.6 years old BMI ≥30 Kg/m <sup>2</sup> T2DM	30	<b>Intervention:</b> Native Banana Starch <b>Control:</b> Soy Milk	<b>Intervention:</b> 15, 14 <b>Control:</b> 15, 14	2 months	<b>Primary:</b> Body weight and insulin sensibility. <b>Secondary:</b> Cholesterol; HDL; Triglycerides; Diastolic blood pressure; Systolic blood pressure; Waist to hip ratio; Calcium; Phosphates.	<b>Yes:</b> Body weight, BMI, waist to hip ratio and triglycerides significantly reduced. <b>No:</b> No significant changes in glucose and HbA1c. A decrease in serum triglycerides in control group. No changes were observed on calcium, phosphate and hematological markers such as white blood cells, platelets and other indexes
Rodriguez-Hernandez <sup>57</sup> Durango 2011	Female Intervention: 46.3 ± 9.1; Control: 45 ± 9.1 years old. BMI ≥30 Kg/m <sup>2</sup>	59	<b>Intervention:</b> low carbs diet (LCD) <b>Control:</b> low fat diet (LFD)	<b>Intervention:</b> 31, 28 <b>Control:</b> 28, 26	6 months	<b>Primary:</b> To evaluate decrease aminotransferase levels.	<b>No:</b> No significant differences in anthropometric and biochemical characteristics between groups

## Anti-obesity interventions in Mexican Population

Rosado <sup>51</sup> Queretaro 2011	NAFLD Female 34 ± 6 years old BMI ≥30 Kg/m <sup>2</sup>	139	<b>Intervention 1:</b> Low fat milk  <b>Intervention 2:</b> Low fat milk with added micronutrients  <b>Control:</b> No milk intake	<b>Intervention 1:</b> 46, 33  <b>Intervention 2:</b> 46, 37  <b>Control:</b> 47, 31	4 months	<b>Primary:</b> To evaluate anthropometrics, body composition, blood glucose levels, lipids profile, C-reactive protein, and blood pressure.	<b>Yes:</b> LFM+M group had significant weight loss than control and LFM+M group. Body fat among LFM+M group members was significantly higher than LFM and control group.  <b>No:</b> No differences between groups in glucose level, blood lipid profile, blood pressure, or C-reactive protein level.
Madero <sup>58</sup> Mexico City 2011	Male and female Intervention 1: 37.56 ± 1.14; Intervention 2: 40.15 ± 1.01. BMI > 25 Kg/m <sup>2</sup>	131	<b>Intervention 1:</b> Low fructose diet  <b>Intervention 2:</b> Moderate natural fructose diet	<b>Intervention 1:</b> 65, 65  <b>Intervention 2:</b> 66, 66	1.5 months	<b>Primary:</b> weight loss.  <b>Secondary:</b> Quality of life scores, blood pressure, lipid profile, serum glucose, insulin resistance, uric acid, and soluble intercellular adhesion molecule-1	<b>Yes:</b> Significant weight loss compared with baseline in both treatments, but higher in the MNF group. Significant improvement in secondary outcomes in both treatments
Tovar <sup>50</sup> Queretaro 2012	Female Intervention 1: 34.62 ± 7.4; Intervention 2: 33.17 ± 7.63; Intervention 3: 32.58 ± 8.13; Control: 33.39 ± 8.72 years old. BMI ≥ 25 Kg/m <sup>2</sup>	144	<b>Intervention 1:</b> Partial meal replacement (PMR) + Inulin (INU)  <b>Intervention 2:</b> PMR  <b>Intervention 3:</b> INU  <b>Control:</b> No additional treatment	<b>Intervention 1:</b> 36, 23  <b>Intervention 2:</b> 36, 28  <b>Intervention 3:</b> 36, 30  <b>Control:</b> 36, 29	3 months	<b>Primary:</b> weight reduction, blood lipids and micronutrients.	<b>Yes:</b> all groups significantly reduced BMI, weight, waist and hip circumference. Subjects in PMR+INU, PMR and INU significantly decreased triglycerides. Fiber intake increased in PMR+INU and INU groups. In PMR and PMR+INU groups some minerals and vitamins intakes increased compared with INU and control groups.
Martinez-Abundis <sup>49</sup> Jalisco 2013	Male and female Intervention: 35.4 ± 4.3; Control: 35.4 ± 3.8 years old.	14	<b>Intervention:</b> Avocado Soybean Unsaponifiable (ASU)  <b>Control:</b> Placebo	<b>Intervention:</b> 7, 7  <b>Control:</b> 7, 7	3 months	<b>Primary:</b> Glucose, triglycerides, HDL-C, leptin, C-reactive protein (CRP), TNFα, adiponectin, erythrocytes, fatty acids and metabolic syndrome.	<b>No:</b> No differences between groups before and after the two treatments in hs-CRP, IL-6, insulin secretion, and insulin sensitivity

## Anti-obesity interventions in Mexican Population

	BMI 30-39.9 Kg/m <sup>2</sup>						
Perichart-Perera <sup>59</sup> Mexico City 2014	Postmenopausal Female  Intervention: 54.81 ± 6.38; Control: 52.65 ± 6.35 years old.  BMI ≥ 25 Kg/m <sup>2</sup>  MetS	118	<b>Intervention:</b> Behavioral therapy  <b>Control:</b> Structured hypocaloric diet	<b>Intervention:</b> 55, 55  <b>Control:</b> 63, 63	6 months	<b>Primary:</b> metabolic syndrome.  <b>Secondary:</b> weight, waist circumference, systolic and diastolic blood pressure, cholesterol, triglycerides, body fat mass	<b>Yes:</b> Higher reduction in MetS prevalence in BT group. Significant decrease in weight and waist circumference in both groups. Control group significantly decreased systolic and diastolic blood pressure, and fat mass measurements. Control group decrease total cholesterol and triglyceride
Hernandez-Cordero <sup>69</sup> Morelos 2014	Women  Intervention: 33.5 ± 6.7; Control: 33.3 ± 6.7 years old.  BMI ≥ 25 Kg/m <sup>2</sup>  MetS	240	<b>Intervention:</b> Water and Education provision (WEP)  <b>Control:</b> Education Provision (EP)	<b>Intervention:</b> 120, 102  <b>Control:</b> 120, 87	9 months	<b>Primary:</b> to determine if replacing SSBs with water affects plasma triglycerides (TGs), weight, and other cardiometabolic factors.	<b>No:</b> No effect on plasma TGs, weight, and other cardiometabolic risks in the ITT analysis.
Macias-Cervantes <sup>60</sup> Guanajuato 2015	Male  Intervention 1: 40 ± 4.8; Intervention 2: 43.5 ± 7.1; Intervention 3: 44.3 ± 5.3 years old.  BMI ≥ 25 Kg/m <sup>2</sup>	43	<b>Intervention 1:</b> Low AGE diet  <b>Intervention 2:</b> Exercise with regular food intake  <b>Intervention 3:</b> Exercise with low AGE diet	<b>Intervention 1:</b> 14  <b>Intervention 2:</b> 14  <b>Intervention 3:</b> 15	3 months	<b>Primary:</b> Identify the effect of a low advanced glycation end product (AGEs) diet, exercise, and a combination of both on circulating AGE levels as well as on plasma lipids and anthropometric parameters. Secondary: blood pressure, beats per minute, Diet-Cal, fasting blood glucose, HDL-C, heart rate, LDL-Cholesterol, VO <sub>2</sub> (oxygen consumption)	<b>Yes:</b> The group with low AGE diet showed differences in weight, BMI, waist circumference, serum AGEs. Group with normal diet + exercise: weight, BMI, waist circumference, heart rate max and VO <sub>2</sub> max. Group with low AGE diet +exercise: weight, BMI, waist, triglycerides, HDL, LDL, serum AGEs, and VO <sub>2</sub> max
Romero-Prado <sup>56</sup> Jalisco	Male and female 42.2 ± 7.5 years	110	<b>Intervention:</b> Flavonoids Diet + Anti-hypertensive therapy	<b>Intervention;</b> 40, 40	6 months	<b>Primary:</b> blood pressure, lipid profile, obesity and inflammation	<b>Yes:</b> SBP, DBP, cholesterol and triglycerides, BMI,

## Anti-obesity interventions in Mexican Population

2015	old BMI 25-34.9 Kg/m <sup>2</sup>  Hypertension according to WHO criteria		(Captopril/Telmisartan)  <b>Control:</b> Anti-hypertensive therapy (captopril/Telmisartan)	<b>Control:</b> 70, 39			waist circumference and CRP showed differences at 3 and 6 months in the intervention group. HDL only when comparing baseline & 6 months.  <b>No:</b> Leptin levels
Campos-Nonato <sup>55</sup>  Morelos  2017	Male and female  47.4 ± 11.5 years old  BMI 25-45 Kg/m <sup>2</sup>  MetS	118	<b>Intervention:</b> High-Protein Diet  <b>Control:</b> Standard-Protein Diet	<b>Intervention:</b> 59,59  <b>Control:</b> 59, 46	6 months	<b>Primary:</b> Evaluate the effect of increased protein intake on weight loss in adults with MetS.  <b>Secondary:</b> (all measured in baseline, 3 and 6 months): fasting blood glucose, fasting insulin, hemoglobin A1c, total cholesterol, high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides, C-reactive protein, creatinine, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase.	<b>Yes:</b> Decreased weight, % of abdominal fat. Differences observed in both groups: waist circumference, Systolic blood pressure, fasting blood glucose, insulin, HOMA index, triglycerides, total cholesterol, VLDL cholesterol. The group SDP, presented a difference in HDL and direct bilirubin.
Leyva-Soto <sup>46</sup>  Baja California  2018	Male and female  Intervention: 23.8 ± 3.4; Control: 23.6 ± 3.5 years old.  BMI > 29 Kg/m <sup>2</sup>  MetS	92	<b>Intervention:</b> Dark chocolate  <b>Control:</b> Milk Chocolate	<b>Intervention:</b> 42, 42  <b>Control:</b> 50, 42	6 months	<b>Primary:</b> Evaluate the genoprotective effect of consuming a flavonoids-rich chocolate.  <b>Secondary:</b> Biochemical parameters related to cardiovascular risk and metabolic syndrome: changes in BMI, waist circumference, Fasting plasma glucose, HOMA, HbA1c, Systolic blood pressure, Diastolic blood pressure, Cholesterol total, triglyceride, Nuclear Abnormalities in Buccal	<b>Yes:</b> abnormalities of the nuclei in the buccal epithelial cells decreases significantly (less than 2%) after 6 months of daily consumption of 2g of dark chocolate. Decreased BMI, waist circumference, Total cholesterol, LDL Cholesterol, triglycerides, HOMA-IR, fasting plasma glucose, systolic and diastolic blood pressure in the group commercial dark



Anti-obesity interventions in Mexican Population

						Epithelial Cells.	chocolate.
Padilla-Camberos <sup>47</sup> Jalisco 2018	Male and female 20-55 years old BMI > 30 Kg/m <sup>2</sup>	28	<b>Intervention:</b> Agave fructans  <b>Control:</b> Maltodextrin	<b>Intervention:</b> 14, 14  <b>Control:</b> 14, 14	3 months	<b>Primary:</b> Effects of agave fructans on weight control, lipid profile, and physical tolerability. Weight, hip, waist, hip waist index, total body fat (%), glucose, serum insulin, total cholesterol, (HDL) and (LDL) cholesterol, triglycerides.  <b>Secondary:</b> Safety assessments were performed. Weight, hip, waist, hip waist index, total body fat (%), glucose, serum insulin, total cholesterol, HDL and LDL cholesterol, triglycerides.	<b>Yes:</b> BMI and triglycerides of the Agave fructans treated group was reduced significantly from the baseline to the final measurements. Hip and waist circumference decreased in both groups.  <b>No:</b> Glucose values

887  
888  
889

Anti-obesity interventions in Mexican Population

890  
891  
892

Table 3. Descriptive characteristics and assessment of Medications.

Pharmacological Intervention							
Author State Year	Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Fanghänel <sup>41</sup> Mexico City 1996	Male and Female  Intervention: 52.1 ± 8.8; Control: 51.2 ± 8.5 years old.  BMI > 27 Kg/m <sup>2</sup>  NIDDM	60	<b>Intervention:</b> Metformin  <b>Control:</b> Insulin	<b>Intervention:</b> 30, 28  <b>Control:</b> 30, 30	3 months	<b>Primary:</b> glucose and lipid metabolism.  <b>Secondary:</b> Glycosylated hemoglobin, BMI, blood pressure.	<b>Yes:</b> Metformin had beneficial effects on insulin resistance, hypertension, overweight, and hyperlipidemia.
Fanghänel <sup>40</sup> Mexico City 1998	Male and Female  Intervention: 49.3 ± 9.6; Control: 47.1 ± 7.3 years old.  BMI >27  T2DM	120	<b>Intervention:</b> Metformin, Insulin  <b>Control:</b> Diet	<b>Intervention:</b> 60, 60  <b>Control:</b> 60, 60	3 months	<b>Primary:</b> levels fibrinogen.	<b>Yes:</b> The insulin group showed decrease on glucose fibrinogen levels and BMI.
Cuellar <sup>36</sup> Mexico City 2000	Male and female  Intervention: 38.44 ± 10.09; Control: 38.62 ± 9.12 years old.  BMI >30 Kg/m <sup>2</sup>	69	<b>Intervention:</b> Sibutramine  <b>Control:</b> Placebo	<b>Intervention:</b> 35, 22  <b>Control:</b> 34, 9	6 months	<b>Primary:</b> Safety and efficacy of sibutramine.  <b>Secondary:</b> waist circumference and waist/hip ratio. Appetite, satiety, and diet adherence were also evaluated.	<b>Yes:</b> Sibutramine induced significant loss of body weight and waist circumference. No significant adverse events. NOTE: Sibutramine was withdrawn in 2010.
Fanghänel <sup>37</sup> Mexico City 2000	Male and female  Intervention: 38.09 ± 10.11; Control: 39.48 ± 10.26 years old.  BMI >30 Kg/m <sup>2</sup>	109	<b>Intervention:</b> Sibutramine  <b>Control:</b> Placebo	<b>Intervention:</b> 55, 40  <b>Control:</b> 54, 44	6 months	<b>Primary:</b> Safety and efficacy of sibutramine 10 mg.  <b>Secondary:</b> Waist circumference and waist/hip ratio, blood pressure and heart rate and clinical laboratory.	<b>Yes:</b> Sibutramine induced significant loss of BMI and waist, but does not significantly affect cardiovascular function. No significant adverse events. NOTE: Sibutramine was withdrawn in 2010.
Fanghänel <sup>38</sup> Mexico City 2001	Male and female  Intervention: 40.1 ± 10.51; Control: 39.0 ± 10.15 years old.	82	<b>Intervention:</b> Sibutramine  <b>Control:</b> Placebo	<b>Intervention:</b> 40, 40  <b>Control:</b> 44, 42	6 months	<b>Primary:</b> Endpoints for the trial were the body weight and BMI.  <b>Secondary:</b> Endpoints were the waist and waist/hip	<b>Yes:</b> Patients had weight gain, but they did not reach the baseline body weight. No significant adverse events. NOTE: Sibutramine was withdrawn in 2010.

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.27.21257740>; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

## Anti-obesity interventions in Mexican Population

	BMI >30 Kg/m <sup>2</sup>					ratio, appetite, satiety and diet adherence and adverse events.	
Zaragoza <sup>35</sup> Mexico City 2001	Male and Female  Intervention 1: 36.84 ± 9.16; Intervention 2: 36.79 ± 10.61; Control: 36.77 ± 9.18 years old.  BMI > 30 Kg/m <sup>2</sup>	210	<b>Intervention 1:</b> D-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg.  <b>Intervention 2:</b> D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.  <b>Control:</b> Placebo	<b>Intervention 1:</b> 69, 59  <b>Intervention 2:</b> 70, 51  <b>Control:</b> 69, 26	6 months	<b>Primary:</b> Update data on the efficacy and safety of two formulations of d-norpseudoephedrine in prolonged-release capsules, which have been used successfully in the treatment of obesity since 1956 and 1995.	<b>Yes:</b> The efficacy and safety of formulations 1 and 2 in the pharmacological treatment of obesity are confirmed, these d-norpseudoephedrine formulations maintain the weight reduction achieved for periods of at least six months, without causing addiction or inducing tolerance with loss effectiveness after a short period. NOTE: Not approved by FDA.
Halpern <sup>45</sup> Multinational 2003	Male and Female  Intervention: 50.88 ± 1.37; Control: 50.79 ± 1.48 years old.  BMI > 27 Kg/m <sup>2</sup>  NIDDM	343	<b>Intervention:</b> Orlistat  <b>Control:</b> Placebo	<b>Intervention:</b> 169, 139  <b>Control:</b> 174, 141	6 months	<b>Primary:</b> To determine if obese non-insulin-dependent diabetic patients lose more weight when treated for 24 weeks with orlistat, in conjunction with a hypocaloric diet plus behavioral counselling, than when treated by placebo plus similar instructions.  <b>Secondary:</b> To evaluate the effects on glucose profile and to determine the tolerability and safety of orlistat.	<b>Yes:</b> Orlistat group lost greater body weight vs. in the placebo group, Orlistat treatment plus diet compared to placebo plus diet was associated with significant improvement in glycaemic control, as reflected decreases in HbA1c, fasting plasma glucose and postprandial glucose and greater improvements than placebo in lipid profile, with reductions in total cholesterol and LDL-c.

## Anti-obesity interventions in Mexican Population

Gonzalez-Ortiz <sup>44</sup> Jalisco 2004	Male and Female  Intervention 1: 53 ± 8; Intervention 2: 53 ± 7; Intervention 3: 53 ± 7 years old.  BMI >27 Kg/m <sup>2</sup>  T2DM with A1c > 8%	104	<b>Intervention 1:</b> Glimepiride  <b>Intervention 2:</b> Metformin  <b>Intervention 3:</b> Glimepiride + Metformin	<b>Intervention 1:</b> 37, 37  <b>Intervention 2:</b> 33, 33  <b>Intervention 3:</b> 34, 34	3 months	<b>Primary:</b> To evaluate the efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with T2DM with secondary failure to glibenclamide.	<b>Yes:</b> The percentage of patients that improved A1C levels to less than 7% were in glimepiride, metformin and their combination groups.
Gómez-García <sup>54</sup> Jalisco 2006	Male  Intervention: 21.8 ± 2.8; Control: 25.1 ± 4.5 years old.  BMI ≥27 Kg/m <sup>2</sup>	14	<b>Intervention:</b> Zinc sulfate  <b>Control:</b> placebo	<b>Intervention:</b> 7, 7  <b>Control:</b> 7, 7	30 days	<b>Primary:</b> Insulin sensitivity, leptin and androgens.  <b>Secondary:</b> Glucose, total cholesterol, HDL-c, LDL-c, VLDL-c, triglycerides, creatinine, uric acid, TT, TL, SHBG.	<b>Yes:</b> Zinc increased the leptin concentrations in obese.  <b>No:</b> No significant changes in insulin sensitivity and androgens after the intervention.
Toplak <sup>34</sup> Multinational 2005	Male and female  Intervention 1: 41.3 ± 11.0; Intervention 2: 41.1 ± 12.1 years old.  BMI 30–43 Kg/m <sup>2</sup>	430	<b>Intervention 1:</b> Orlistat + Diet -500 kcal  <b>Intervention 2:</b> Orlistat + Diet -1000kcal	<b>Intervention 1:</b> 215, 141  <b>Intervention 2:</b> 215, 154	12 months	<b>Primary:</b> To determine the effect of two different levels of energy deficit on weight loss in obese patients treated with orlistat.	<b>No:</b> Treatment with orlistat was associated with clinically beneficial weight loss, irrespective of the prescribed dietary energy restriction.
Gonzalez-Ortiz <sup>33</sup> Jalisco 2006	Male and Female  Intervention: 37.3 ± 6.7; Control: 38.5 ± 5.8 years old.  BMI: 25-35 Kg/m <sup>2</sup>  Dyslipidaemia	12	<b>Intervention:</b> Ezetimibe  <b>Control:</b> Placebo	<b>Intervention:</b> 6, 6  <b>Control:</b> 6, 6	3 months	<b>Primary:</b> To evaluate the effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidemic patients.	<b>Yes:</b> Ezetimibe administered for 90 days decreased total and low-density lipoprotein cholesterol concentrations.  <b>No:</b> Insulin sensitivity.
Meaney <sup>32</sup> Mexico City 2008	Male and female  Intervention: 49 ± 10; Control: 49 ± 8 years old.  MetS	60	<b>Intervention:</b> Metformin  <b>Control:</b> Diet	<b>Intervention:</b> 30, 22  <b>Control:</b> 28, 17	12 months	<b>Primary:</b> To evaluate the effect of metformin on metabolic syndrome in IGT patients.	<b>Yes:</b> Metformin has effect on endothelial function and nitroxidation. <b>No:</b> No-effect on BMI.
Hernandez-Gonzalez <sup>52</sup>	Male and Female	12	<b>Intervention:</b> Chitosan	<b>Intervention:</b> 6, 6	3 months	<b>Primary:</b> Insulin sensitivity.	<b>Yes:</b> Increased insulin sensitivity and decrease

## Anti-obesity interventions in Mexican Population

Jalisco 2010	Intervention: 41.6 ± 6.3; Control: 42.6 ± 5.6 years old.  BMI: 30-40 Kg/m <sup>2</sup>  Without DM		<b>Control:</b> Placebo	<b>Control:</b> 6, 6		<b>Secondary:</b> Glucose, HDL-c, LDL-c and triglycerides.	weight, BMI, waist circumference and TG.
Martinez-Abundis <sup>31</sup>  Jalisco 2010	Male and female  Intervention 1: 29.5 ± 6.3; Intervention 2: 26.1 ± 4.0; Intervention 3: 29.6 ± 5.5 years old.  BMI 30-40 Kg/m <sup>2</sup>	18	<b>Intervention 1:</b> Placebo and metformin  <b>Intervention 2:</b> Sibutramine and placebo  <b>Intervention 3:</b> Sibutramine and metformin	<b>Intervention 1:</b> 9, 9  <b>Intervention 2:</b> 9, 9  <b>Intervention 3:</b> 9, 9	3 months	<b>Primary:</b> To compare the effect of metformin and sibutramine as monotherapy or as combined therapy on insulin sensitivity and adiposity in obese patients.  <b>Secondary:</b> To evaluated Blood pressure, ITT, glucose, total cholesterol, LDL-c, HDL-c, triglycerides.	<b>Yes:</b> The three pharmacological interventions reduced BMI at different magnitudes. Metformin improved insulin sensitivity. Sibutramine decreased adiposity. Metformin monotherapy or combined with sibutramine had beneficial effect on lipid profile.
Ramos-Zavala <sup>39</sup>  Jalisco 2011	Male and female  Intervention: 47.5 ± 5.3; Control: 47.7 ± 5.2 years old.  BMI > 25  T2DM with <6 months since diagnosis	40	<b>Intervention:</b> Diacerein  <b>Control:</b> Placebo	<b>Intervention:</b> 20, 20  <b>Control:</b> 20, 20	2 months	<b>Primary:</b> Insulin secretion and metabolic control (included interleukin IL-1β, TNF-a, IL-6).	<b>Yes:</b> Significant increases in first, late and total insulin, fasting glucose and A1c levels, TNF-a, IL-6.  <b>No:</b> Without significant differences in total cholesterol, HDL-c, LDL-c and triglycerides, VLDL-c and metabolized glucose
González-Acevedo <sup>30</sup>  San Luis Potosi 2013	Women  Intervention 1: 31.65 ± 7.41; Intervention 2: 28.45 ± 8.15; Control: 30.70 ± 6.87 years old  BMI > 30 Kg/m <sup>2</sup>	60	<b>Intervention 1:</b> 1 g of Omega-3  <b>Intervention 2:</b> 2 g of Omega-3  <b>Control:</b> Placebo+ Vitamin E (200 IU)	<b>Intervention 1:</b> 20, 20  <b>Intervention 2:</b> 20, 20  <b>Control:</b> 20, 20	3 months	<b>Primary:</b> To assess the effect of omega-3 supplementation on BMI, WHI and body composition of obese women using bioelectrical impedance.	<b>Yes:</b> Supplementation significantly reduced weight, BMI, and total fat mass compared to the control group, a dose-response effect, but these effect depended on the time and amount of Omega 3 supplemented, when the degree of compliance of exercise, adherence to the diet and age were controlled.

## Anti-obesity interventions in Mexican Population

Sánchez-Muñoz <sup>29</sup> Mexico City 2013	Women 25-60 years old BMI >24,9 Kg/m <sup>2</sup>	19	<b>Intervention:</b> Metformin <b>Control:</b> Exercise	<b>Intervention:</b> 9, 8 <b>Control:</b> 10, 8	3 months	<b>Primary:</b> To establish the effectiveness of aerobic exercise and its influence in reducing cardiovascular risk in overweight or obese women with NAFLD.	<b>Yes:</b> It was significant changes in Arterial tension, HOMA-IR and insulin. <b>No:</b> Was not significant differences in fatty liver.
Hernandez-Corona <sup>48</sup> Jalisco 2014	Male and female Intervention: 45.4 ± 7.3; Control: 42.4 ± 3.7 years old. BMI: 25-34.9 Kg/m <sup>2</sup>	25	<b>Intervention:</b> F Fucoidan <b>Control:</b> Placebo	<b>Intervention:</b> 13, 11 <b>Control:</b> 12, 8	3 months	<b>Primary:</b> Evaluate changes in insulin secretion and insulin resistance. <b>Secondary:</b> Weight, blood pressure, glucose, total cholesterol, HDL-c, TG and IR.	<b>Yes:</b> Significant decrease in DBP and LDL-c, Increase in insulin levels, HOMA B-cell and HOMA IR. <b>No:</b> BMI.
Hernandez-Bastida <sup>43</sup> Mexico City 2015	Male and female 18-65 years old BMI 25-40 Kg/m <sup>2</sup> T2DM	120	<b>Intervention:</b> Topiramate + Phentarmine <b>Control:</b> Placebo + Phentarmine	<b>Intervention:</b> 60, 54 <b>Control:</b> 60, 53	3 months	<b>Primary:</b> Efficacy and safety of the combination of phentermine plus topiramate. <b>Secondary:</b> To evaluate the impact of the combination over risk and safety factors.	<b>Yes:</b> The combination showed reduction in weight, BMI, waist, circumference, lipids and glucose. The most frequent adverse events were paresthesia and dry mouth, these effects decreased in frequency and intensity during the study.
O'Neil <sup>27</sup> Multinational 2016	Male and female <b>Hispanic Age:</b> Intervention: 41.4 ± 11.4; Control: 41.0 ± 11.7 years old. BMI ≥27 Kg/m <sup>2</sup> with at least 1 comorbid condition or BMI ≥30 Kg/m <sup>2</sup>	5131 <b>Hispanic:</b> 534	<b>Intervention:</b> Liraglutide <b>Control:</b> Placebo	<b>Intervention:</b> 3289, 3289 <b>Control:</b> 1842, 1842 <b>Hispanic participants:</b> <b>Intervention:</b> 341, 341 <b>Control:</b> 193, 193 (their data were combined with other ethnic groups)	3 studies of 56 weeks 1 study of 32 weeks	<b>Primary:</b> Efficacy and safety of liraglutide. <b>Secondary:</b> Weight and risk factors.	<b>Yes:</b> Efficacy and safety were largely similar between Hispanic and non-Hispanic.

## Anti-obesity interventions in Mexican Population

Sánchez-Rodríguez <sup>28</sup> Mexico City 2016	Healthy postmenopausal women or with MetS.  Healthy women: Intervention: 52 ± 0.6; Control: 53 ± 0.7 years old.  MetS women: Intervention: 52 ± 0.7; Control: 53 ± 0.9 years old.	100	<b>Intervention:</b> Hormone therapy  <b>Control:</b> Placebo	<b>Intervention:</b> 50, 46  <b>Control:</b> 50, 45	6 months	<b>Primary:</b> Oxidative stress.	<b>Yes:</b> After 6 months, MetS decreased in the hormone treated group (48%), triglycerides and HDL-c; the controls did not show differences. SS in MSW-HT decreased (3.8 ± 0.3 to 1.7 ± 0.3, p < 0.05) and Oxidative stress was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%).  In placebo groups there was no change.
Mendez-del Villar <sup>42</sup> Jalisco 2017	Male and Female  Intervention: 41.3 ± 9.7; Control: 54 ± 3.5 years old.  BMI: 25-34.9 Kg/m <sup>2</sup>  T2DM and inadequate glycemic control	12	<b>Intervention:</b> Metformin + Diacerein  <b>Control:</b> Metformin	<b>Intervention:</b> 6, 6  <b>Control:</b> 6, 6	3 months	<b>Primary:</b> Glycemic control.	<b>Yes:</b> Significant decrease in fasting glucose, postprandial glucose and A1C.
Gonzalez-Heredia <sup>24</sup> Jalisco 2017	Male and female  Intervention: 49.3 ± 5.7; Control: 51.9 ± 6.4 years old.  BMI 25–34.9 Kg/m <sup>2</sup>  Impaired Glucose Tolerance	16	<b>Intervention:</b> Linagliptin  <b>Control:</b> Metformin	<b>Intervention:</b> 8, 8  <b>Control:</b> 8, 8	3 months	<b>Primary:</b> To assess the effect of linagliptin versus metformin on glycemic variability in patients with IGT.	<b>Yes:</b> Group with linagliptin had decrease in glucose levels at 120 min of OGTT.  <b>No:</b> No significant differences in the AUC, MAGE, SD glucose, CV of glucose, and MBG between groups.
Gonzalez-Ortiz <sup>25</sup> Jalisco 2017	Male  Intervention: 40.2 ± 7.9; Control: 38.4 ± 6.4 years old.  BMI 30-39.9 Kg/m <sup>2</sup>	18	<b>Intervention:</b> Tadalafil  <b>Control:</b> Placebo	<b>Intervention:</b> 9, 9  <b>Control:</b> 9, 9	28 days	<b>Primary:</b> Blood pressure, cholesterol, triglycerides, HDL-c, LDL-c, glucose.	<b>No:</b> After the administration of tadalafil there were no significant differences in total insulin secretion first phase of insulin secretion and insulin sensitivity. No significant differences were shown in other measurements.
Le Roux <sup>26</sup> Multinational 2017	Male and female  Intervention: 47.5 ± 11.7; Control: 47.3 ± 11.8 years old.	2254 <b>Hispanic:</b> 213	<b>Intervention:</b> Liraglutide  <b>Control:</b> Placebo	<b>Intervention:</b> 1505, 783  <b>Control:</b> 749, 327	40 months (3.3 years)	<b>Primary:</b> Evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.	<b>Yes:</b> Time to onset of diabetes over the 40 months among all randomized individuals was 2.7 times longer with liraglutide than

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.27.21257740>; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

## Anti-obesity interventions in Mexican Population

	BMI $\geq 27$ Kg/m <sup>2</sup>  Dyslipidemia, or hypertension, or both			<b>Hispanic participants</b> <b>Intervention:</b> 143  <b>Control:</b> 70  (their data were gathered with other individuals)		<b>Secondary:</b> GLP-1 receptor agonist, waist circumference (cm), glycated hemoglobin (%), 2-h plasma glucose during OGTT (mmol/L), Free fatty acids (mmol/L), Blood pressure (mm Hg).	with placebo.  Greater weight loss than placebo at month 40: BMI, waist circumference, glycated hemoglobin, fasting glucose, fasting insulin, fasting C-peptide, glucose levels in OGTT, systolic and diastolic blood pressure, and heart rate.
--	---	--	--	---	--	--	---

893 NIDDM: Non-insulin dependent diabetes mellitus; BMI: Body mass index; T2DM: Type 2 diabetes mellitus; FDA: Food and Drug Administration; A1c: Glycated hemoglobin; HDL: High  
 894 density lipoprotein; LDL: Low density lipoproteins; VLDL: Very low density lipoprotein; TT: Total testosterone, TL: Free testosterone, SHBG: Sex Hormone Binding Globulin; MetS:  
 895 Metabolic syndrome; IGT: Impaired glucose tolerance; TG: Triglycerides; ITT: Insulin tolerance test; IL-1 $\beta$ : Interleukin 1 beta; IL-6: Interleukin-6; TNF-a: Tumour Necrosis Factor alpha;  
 896 WHI: Waist Hip Index; NAFLD: Non-alcoholic fatty liver disease; IR: Insulin resistance; HOMA-IR: Homeostasis model assessment of IR; HOMA B-cells: Homeostatic Model  
 897 Assessment-beta-cell function; SS: Stress score; MSW-HT: MetS women were assigned to HT (hormone therapy); HW-HT: Healthy-hormone therapy; OS: Oxidative stress; OGTT:  
 898 Oral glucose tolerance test; AUC: Area under the curve; MAGE: Mean amplitude of glycemic excursion, SD: Standard deviation; CV: Coefficient of variation; MBG: Mean blood  
 899 glucose; GLP-1: Glucagon-like peptide-1.

900

901



902 Table 4. Descriptive characteristics and assessment of Medications.  
903

Surgical and Alternative Intervention							
Author State Year	Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Robles-Cervantes <sup>68</sup> Jalisco 2007	Female  Intervention: 34.0 ± 3.7; Control: 34.6 ± 3.6 years old.  BMI: 30-33 Kg/m <sup>2</sup>	12	<b>Intervention:</b> Liposuction and diet  <b>Control:</b> Diet	<b>Intervention:</b> 6, 6  <b>Control:</b> 6, 6	6 months	<b>Primary:</b> Visceral fat, Insulin sensitivity, leptin and tumor necrosis factor alfa.  <b>Secondary:</b> Glucose, Creatinine, Uric acid, Total cholesterol, HDL cholesterol, Triglycerides.	<b>Yes:</b> Leptin correlated with the subcutaneous fat.  <b>No:</b> no significant difference in insulin sensitivity and did not correlate with subcutaneous fat, leptin, or TNF-alpha.
Arceo-Olaiz <sup>67</sup> Mexico City 2008	Male and Female  Intervention: 36.5 ± 9.7; Control: 37.8 ± 9.6 years old.  BMI: 40-55 kg/m2	60	<b>Intervention:</b> Laparoscopic roux- en - y gastric bypass (LRYGB)  <b>Control:</b> banded LRYGB (BLRYGB)	<b>Intervention:</b> 30, 30  <b>Control:</b> 30, 30	24 months	<b>Primary:</b> Weight loss	<b>No:</b> The studied groups did not have significant differences in weight loss at 6, 12, and 24 months. The frequency of complication was similar in both groups.
García-Vivas <sup>63</sup> Durango 2014	Women  18-45 years old  BMI ≥25 Kg/m <sup>2</sup>  without known MetS	138	<b>Intervention:</b> Accupunture  <b>Control:</b> Sham Accupunture	138, 99	2 months	<b>Primary:</b> anthropometric and biochemical	<b>Yes:</b> Acupoint catgut embedding therapy moxibustion produced significant reduction in body weight insulin and HOMA-IR
Alvarado-Reynoso <sup>65</sup> Mexico City 2019	Male and Female  Intervention: 42.1 ± 3.2; Control: 37.8 ± 3.3 years old.  BMI ≥ 25 Kg/m <sup>2</sup>	45	<b>Intervention:</b> repetitive transcranial magnetic stimulation) rTMS  <b>Control:</b> sham rTMS	<b>Intervention:</b> 22, 18  <b>Control:</b> 23, 19	2 weeks	<b>Primary:</b> body weight, food craving, auto perception, general health, depression and anxiety	<b>Yes:</b> In the rTMS-treated group reduced body weight, anxiety, and food craving. General health survey domain improved on physical functioning, emotional role, and vitality. The body shape questionnaire improved.
Hernandez-Lepe <sup>64</sup> Chihuahua 2019	Male  25 ± 5 years old  BMI >25 Kg/m <sup>2</sup>  Sedentary	52	<b>Intervention:</b> spirulina maxima  <b>Control:</b> placebo	<b>Intervention:</b> 26, 26  <b>Control:</b> 26, 26	3 months	<b>Primary:</b> plasma lipid profile and antioxidant capacity	<b>Yes:</b> BMI, total cholesterol, triglycerides and LDL-C decreased. HDL-C increased in all treatment groups. Participants with known dyslipidemia had higher response.

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.27.21257740>; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



905 Table 5. Network meta-analysis results matrix.

<b>Matrix A: Drugs (Non-diabetic participants)</b>					
<b>BMI (Reference: placebo)</b>					
<b>DHA 470 + EPA 580</b>	0.072 (-0.672, 0.815)	0.143 (-0.852, 1.138)	0.129 (-0.872, 1.130)	-0.365 (-1.192, 0.462)	-0.816 (-1.582, -0.049)
-0.072 (-0.815, 0.672)	<b>DHA 940 + EPA 1160</b>	0.071 (-0.927, 1.070)	0.057 (-0.947, 1.061)	-0.436 (-1.267, 0.394)	-0.888 (-1.658, -0.117)
-0.143 (-1.138, 0.852)	-0.071 (-1.070, 0.927)	<b>Form1</b>	-0.014 (-0.570, 0.541)	-0.508 (-1.214, 0.198)	-0.959 (-1.593, -0.324)
-0.129 (-1.130, 0.872)	-0.057 (-1.061, 0.947)	0.014 (-0.541, 0.570)	<b>Form2</b>	-0.493 (-1.208, 0.221)	-0.944 (-1.588, -0.301)
0.365 (-0.462, 1.192)	0.436 (-0.394, 1.267)	0.508 (-0.198, 1.214)	0.493 (-0.221, 1.208)	<b>Liraglutide</b>	-0.451 (-0.761, -0.141)
0.816 ( 0.049, 1.582)	0.888 ( 0.117, 1.658)	0.959 ( 0.324, 1.593)	0.944 ( 0.301, 1.588)	0.451 ( 0.141, 0.761)	<b>Plc</b>
<b>Matrix B: Drugs (Diabetic participants)</b>					
<b>BMI (Reference: metformin)</b>					
<b>Diac+Met</b>	-0.080 (-1.307, 1.147)	-0.143 (-1.374, 1.088)	-0.774 (-2.026, 0.478)	0.124 (-1.009, 1.257)	
0.080 (-1.147, 1.307)	<b>Glim</b>	-0.063 (-0.529, 0.403)	-0.694 (-1.404, 0.017)	0.204 (-0.266, 0.675)	
0.143 (-1.088, 1.374)	0.063 (-0.403, 0.529)	<b>Glim+Met</b>	-0.631 (-1.349, 0.087)	0.267 (-0.214, 0.749)	
0.774 (-0.478, 2.026)	0.694 (-0.017, 1.404)	0.631 (-0.087, 1.349)	<b>Insulin</b>	0.898 ( 0.366, 1.431)	
-0.124 (-1.257, 1.009)	-0.204 (-0.675, 0.266)	-0.267 (-0.749, 0.214)	-0.898 (-1.431, -0.366)	<b>Met</b>	

906  
 907 Matrix A represent the estimates of the effect of treatments (standardized mean differences and 95%CI) relative to placebo. The  
 908 dosage of DHA and EPA are in mg per day. Form1: D-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine  
 909 0.36 mg, aloin 16.2 mg. Form2: D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg. These two formulations are not  
 910 approved by FDA. Plc: Placebo. Matrix B shows estimates of the effect of treatments (standardized mean differences) relative to  
 911 metformin in patients with diabetes. Diac: Diacerin; Gim: Glimepiride; Met: Metformin.

## Anti-obesity interventions in Mexican Population

912  
913  
914  
915